Gene Therapy For Diabetic Neuropathy Using An Hgf Isoform

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of U.S. application Ser. No. 14/355,792, filed May 30, 2014, which is a National Stage of International Application No. PCT/KR2012/002224, filed Mar. 27, 2012; which claims the benefit of KR Application No. 10-2011-0113786, filed Nov. 3, 2011, each of which is incorporated in its entirety by reference.

SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 30, 2018, is named 37210US_CRF_sequencelisting.txt, and is 77,473 bytes in size.

TECHNICAL FIELD

[0003] The present invention relates to a composition for the prevention or treatment of diabetic neuropathy, comprising, as active ingredients, different types of isoforms of hepatocyte growth factor (HGF) or at least one polynucleotide encoding the isoforms.

BACKGROUND ART

[0004] Hepatocyte growth factor (HGF) is a heparin-binding glycoprotein also known as scatter factor or hepatopoietin-A. HGF that has been first identified as a potent hepatotropic growth factor (Nakamura et al., Nature 342:440 (1989)) is a mesenchymal-derived heparin-binding protein having multiple biological effects such as mitogenesis, motogenesis, and morphogenesis of various types of cells. A gene encoding HGF is located at chromosome 7q21.1, and involves 18 exons and 17 introns (Seki T., et al., Gene 102:213-219 (1991)).

[0005] A transcript of about 6 kb is transcribed from the HGF gene, and then a full-length polypeptide HGF precursor (f1HGF) composed of 728 amino acids is synthesized therefrom, wherein the f1HGF includes the following domains: N-terminal hairpin loop-kringle 1-kringle 2-kringle 3-kringle 4-inactivated serine protease. Simultaneously, several other HGF polypeptide isoforms are synthesized by an alternative splicing of the HGF gene. Known isoforms include deleted variant HGF (deletion of five amino acids from kringle 1 of the full-length HGF), NK1 (N-terminal hairpin loop-kringle 1), NK2 (N-terminal hairpin loop-kringle 1-kringle 2), and NK4 (N-terminal hairpin loop-kringle 1-kringle 2-kringle 3-kringle 4). In addition, there are allelic variants of each isoform. The biologically inactive precursors may be converted into active forms of disulfide-linked heterodimer by protease in serum. In the heterodimers, the alpha chain having a high molecular weight forms four kringle domains and an N-terminal hairpin loop like a pre-activated peptide region of plasminogen. The kringle domains of a triple disulfide-bonded loop structure consisting of about 80 amino acids may play an important role in protein-protein interaction. The low-molecular weight beta chain forms an inactive serine protease-like domain. dHGF consisting of 723 amino acids is a polypeptide with deletion of five amino acids in the first kringle domain of the alpha chain, i.e., F, L, P, S and S, due to alternative splicing between exon 4 and exon 5.

[0006] In vivo, two isoforms of HGF (f1HGF having 728 amino acids and dHGF having 723 amino acids) are generated through alternative splicing between exon 4 and exon 5. Both of f1HGF and dHGF are the same in view of several biological functions, but are different from each other in terms of immunological characteristics and several biological characteristics. For example, f1HGF exhibits about 20-fold, 10-fold and 2-fold higher activities than dHGF in terms of promoting DNA synthesis in human umbilical cord venous endothelial cell, arterial smooth muscle cell, and NSF-60 (murine myeloblast cell), respectively. dHGF exhibits about 3-fold and 2-fold higher activities than f1HGF in terms of promoting DNA synthesis of LLC-PK1 (pig kidney epithelial cells), and OK (American opossum kidney epithelial cells), and mouse interstitial cells, respectively. In addition, f1HGF exhibits 70-fold higher solubility in PBS than dHGF. Several anti-dHGF monoclonal antibodies recognize only dHGF and f1HGF or a reduced form of dHGF, which implies that the three-dimensional structures of HGF and dHGF are different.

[0007] HGF has been shown to stimulate angiogenesis by regulating the growth of endothelial cells and migration of vascular smooth muscle cells. Due its angiogenic activity, HGF is regarded as one of the promising candidates in therapeutic angiogenesis. "Therapeutic angiogenesis" means an intervention that utilizes angiogenic factors as recombinant proteins or genes, for the treatment of ischemic diseases, such as coronary artery disease (CAD) or peripheral artery disease (PAD). HGF has been also known to stimulate not only the growth but also the migration of endothelial cells (Bussolino et al., J Cell Biol. 119:629 (1992); Nakamura et al., J Hypertens 14:1067 (1996)), and has been tested for its role as a re-endothelialization stimulating agent (Yasuda et al., Circulation 101:2546 (2000); Hayashi et al., Gene Ther 7:1664 (2000)). All of the studies on HGF gene therapy described above have been conducted by using f1HGF cDNA encoding 728 amino acids, but not dHGF cDNA encoding 723 amino acids.

[0008] Diabetic Neuropathies are serious and dangerous diabetic complications, and, in many cases, they lead to simultaneous occurrence of several types of neuropathies. Diabetic neuropathies are largely classified into polyneuropathy and focal neuropathy. The polyneuropathy includes hyperglycemic neuropathy, distal symmetric polyneuropathy, autonomic neuropathy, acute sensory neuropathy, acute painful sensory neuropathy, chronic sensorimotor neuropathy, and the like. The focal neuropathy includes cranial neuropathy, truncal neuropathy, limb neuropathy, thoracolumbar radiculoneuropathy, lumbosacral radiculoplexus neuropathy, and the like (Andrew J. M. et al., Diabetescare 28:956-962 (2005); J Gareth Llewelyn et al., J Neurol Neurosurg Psychiatry 74:15-19 (2003)). Diabetic Neuropathy has severe pain and loss of mobility as its representative symptoms. According to statistics from the U.S., 60 to 70% of people with diabetes have been known to have diabetic neuropathy (American Diabetes Association (ADA), National Institute of Diabetes and Digestive and Kidney Disease (NIDDK)), and 3.9 million or more diabetic patients aged 40 or over have been known to have diabetic neuropathy. The economic cost of these is estimated to be up to $13.7 billion per year, and this cost is expected to increase continuously.

[0009] Currently permitted drugs for diabetic neuropathy are only Lyrica.RTM. of Pfizer and Cymbalta.RTM. of Eli Lilly. However, these two drugs are merely a kind of painkiller alleviating pains shown in diabetic neuropathy, and may not delay the progress of disease or fundamentally ameliorate symptoms. Besides this medicine treatment, allopathy for pain relief, motor function improvement, and mental stress reduction are being used. There is no fundamental treatment at present, and the control of diabetes through dietary control is the only way to minimize the occurrence of diabetic neuropathy. Therefore, new novel of therapeutic agents capable of suppressing or ameliorating the progress of diabetic neuropathy need to be developed.

[0010] Throughout this application, several patents and publications are referenced and citations are provided in parentheses. The disclosure of these patents and publications is incorporated into this application in order to more fully describe this invention and the state of the art to which this invention pertains.

DETAILED DESCRIPTION OF THE INVENTION

Technical Problem

[0011] The present inventors have endeavored to develop therapeutic agents capable of effectively treating diabetic neuropathy. As a result, the present inventors have found that the expression of different types of isoforms of hepatocyte growth factor (HGF) can effectively treat diabetic neuropathy, and then completed the present invention.

[0012] Therefore, the present invention has been made in view of the above-mentioned problems, and an aspect of the present invention is to provide a pharmaceutical composition for preventing or treating diabetic neuropathy.

[0013] Another aspect of the present invention is to provide a method for preventing or treating diabetic neuropathy.

[0014] Other purposes and advantages of the present disclosure will become clarified by the following detailed description of the invention, claims, and drawings.

Technical Solution

[0015] In accordance with an aspect of the present invention, there is provided a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, the composition including, as active ingredients, different types of isoforms of hepatocyte growth factor (HGF) or at least one polynucleotide encoding the isoforms.

[0016] In accordance with another aspect of the present invention, there is provided a method for the prevention or treatment of diabetic neuropathy, the method including administering to a mammal a composition containing, as active ingredients, different types of isoforms of hepatocyte growth factor (HGF) or at least one polynucleotide encoding the isoforms.

[0017] The present inventors have endeavored to develop therapeutic agents capable of effectively treating diabetic neuropathy. As a result, the present inventors have found that the expression of different types of isoforms of hepatocyte growth factor (HGF) can effectively treat diabetic neuropathy.

[0018] The present invention is mainly characterized in that different types of isoforms of hepatocyte growth factor (HGF) or at least one polynucleotide sequence encoding the isoforms are used to prevent and treat diabetic neuropathy.

[0019] Treatment strategy of the present invention may be largely classified into two types: protein therapy and gene therapy.

[0020] According to the protein therapeutic agent strategy of the present invention, two or more types of isomeric proteins of HGF are used. The two or more types of isomeric proteins of HGF may be provided by one polypeptide or separate polypeptides. Preferably, the two or more types of isomeric proteins of HGF are provided by one polypeptide.

[0021] According to the gene therapeutic agent strategy of the present invention, at least one nucleotide sequence encoding two or more types of isomers of HGF is used. A polynucleotide sequence encoding two or more types of isomers of HGF may be provided by one polynucleotide or separate polynucleotides. Preferably, the polynucleotide sequence encoding two or more types of isomers of HGF is provided by one polynucleotide.

[0022] Hereinafter, the present invention will be described in detail.

[0023] As used herein, the term "isoform of HGF" refers to an HGF polypeptide having an amino acid sequence that is at least 80% identical to a naturally occurring HGF amino acid sequence in an animal, including all allelic variants. For example, the isoform of HGF has a meaning including all of normal forms or wild types of HGF and various variants of HGF (e.g., splice variants and deletion variants).

[0024] According to a preferable embodiment of the present invention, the different types of isoforms of HGF include two or more isoforms selected from the group consisting of full-length HGF, (f1HGF), deleted variant HGF (dHGF), NK1, NK2, and NK4.

[0025] According to a more preferable embodiment of the present invention, the different types of isoforms of HGF of the present invention include f1HGF and dHGF.

[0026] As used herein, the term "f1HGF" refers to a sequence of amino acids 1-728 of the HGF protein from an animal, preferably a mammal, and more preferably a human. Human f1HGF includes the amino acid sequence of SEQ ID NO: 1.

[0027] As used herein, the term "dHGF" refers to the deleted variant of the HGF protein produced by alternative splicing of the HGF gene from an animal, and preferably a mammal. More preferably, the term "dHGF" refers to human HGF with deletion of five amino acids (F, L, P, S, and S) in the first kringle domain of the alpha chain from the full length HGF sequence, consisting of 723 amino acids. The human dHGF includes the amino acid sequence of SEQ ID NO: 2.

[0028] As used herein, the term "NK1" refers to an isoform of HGF from an animal, preferably a mammal, and more preferably a human, consisting of the N-terminal hairpin loop and the kringle 1 domain. Human NK1 includes the amino acid sequence of SEQ ID NO: 3.

[0029] As used herein, the term "NK2" refers to an isoform of HGF from an animal, preferably a mammal, and more preferably a human, consisting of the N-terminal hairpin loop, the kringle 1 domain, and the kringle 2 domain. Human NK2 includes the amino acid sequence of SEQ ID NO: 4.

[0030] As used herein, the term "NK4" refers to an isoform of HGF from an animal, preferably a mammal, and more preferably a human, consisting of the N-terminal hairpin loop, the kringle 1 domain, the kringle 2 domain, the kringle 3 domain, and the kringle 4 domain. Human NK4 includes the amino acid sequence of SEQ ID NO: 5.

[0031] According to a preferable embodiment of the present invention, the different types of isoforms of HGF may be encoded by separate polynucleotides or a single polynucleotide. Herein, the different types of isoforms of HGF may include two or more polynucleotides when being encoded by separate polynucleotides, and the different types of isoforms of HGF may include at least one polynucleotide when being encoded by a single polynucleotide.

[0032] The polynucleotide of the present invention may be operatively linked to at least one regulatory sequence (e.g., a promoter or an enhancer) regulating expression of the isoforms of HGF.

[0033] When the two or more types of isoforms of HGF are encoded by separate polynucleotides, an expression cassette may be constructed in two manners. According to a first manner, the expression cassette is constructed by linking an expression regulatory sequence to a coding sequence (CDS) of each isoform. According to a second manner, the expression cassette is constructed by using an internal ribosomal entry site (IRES), like "expression regulatory sequence-CDS of first isomer-IRES -CDS of second isomer-transcription termination sequence". The IRES allows the gene translation to start at the IRES sequence, thereby resulting in the expression of two genes of interest in the same construct.

[0034] When two or more types of isoforms of HGF are encoded by a single polynucleotide, the polynucleotide encoding all the two or more types of isoforms of HGF is operatively linked to a single expression regulatory sequence.

[0035] Herein, the isoforms of HGF may be encoded by a hybrid HGF gene simultaneously expressing two or more different types of isoforms of HGF, e.g., f1HGF and dHGF.

[0036] According to a preferable embodiment of the present invention, the hybrid HGF gene includes cDNA corresponding exon 1-18 of human HGF and intron 4 of a human HGF gene or its fragment, which is inserted between exon 4 and exon 5 of the cDNA.

[0037] According to a more preferable embodiment of the present invention, the hybrid HGF gene includes a nucleotide sequence selected from the group consisting of SEQ ID NO: 7 to SEQ ID NO: 14.

[0038] The hybrid HGF gene including intron 4 is 7112 bp long and includes the nucleotide sequence of SEQ ID NO: 7. The hybrid HGF gene may selectively include a fragment of intron 4 between exon 4 and exon 5 of HGF cDNA.

[0039] According to a preferable embodiment of the present invention, the sequence additionally inserted between exon 4 and exon 5 includes: intron 4 of the human HGF gene, nucleotides 392-2247, nucleotides 392-727, nucleotides 2229-5471, nucleotides 5117-5471, nucleotides 3167-5471, nucleotides 4167-5471, or a combination thereof, of SEQ ID NO: 7.

[0040] More preferably, the sequence additionally inserted between exon 4 and exon 5 of the therapeutic nucleotide sequence used in the present invention is (i) nucleotides 392-2247 and nucleotides 2229-5471 of SEQ ID NO: 7; (ii) nucleotides 392-2247 and nucleotides 5117-5471 of SEQ ID NO: 7; (iii) nucleotides 392-2247 and nucleotides 3167-5471 of SEQ ID NO: 7; (iv) nucleotides 392-2247 and nucleotides 4167-5471 of SEQ ID NO: 7; (v) nucleotides 392-727 and nucleotides 2229-5471 of SEQ ID NO: 7; (vi) nucleotides 392-727 and nucleotides 5117-5471 of SEQ ID NO: 7; (vii) nucleotides 392-727 and nucleotides 3167-5471 of SEQ ID NO: 7; or (viii) nucleotides 392-727 and nucleotides 4167-5471 of SEQ ID NO: 7.

[0041] The therapeutic nucleotide sequence of the present invention according to the sequence additionally inserted between exon 4 and exon 5 is summarized as below. (i) (exon 1 to exon 4)-(nucleotides 392-2247-nucleotides 2297-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); (ii) (exon 1 to exon 4)-(nucleotides 392-2247-nucleotides 5117-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); (iii) (exon 1 to exon 4)-(nucleotides 392-2247-nucleotides 3167-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); (iv) (exon 1 to exon 4)-(nucleotides 392-2247-nucleotides 4167-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); (v) (exon 1 to exon 4)-(nucleotides 392-727-nucleotides 2229-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); (vi) (exon 1 to exon 4)-(nucleotides 392-727-nucleotides 5117-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); (vii) (exon 1 to exon 4)-(nucleotides 392-727-nucleotides 3167-5471 of SEQ ID NO: 7)-(exon 5 to exon 18); and (viii) (exon 1 to exon 4)-(nucleotides 392-727-nucleotides 4167-5471 of SEQ ID NO: 7)-(exon 5 to exon 18).

[0042] Herein, the hybrid HGF gene including a fragment of intron 4 is named "HGF-X". The HGF-X includes HGF-X2, HGF-X3, HGF-X4, HGF-X5, HGF-X6, HGF-X7, and HGF-X8 having nucleotide sequences of SEQ ID NO: 8 to SEQ ID NO: 14, respectively.

[0043] The amino acid sequences and nucleotide sequences of HGF isoforms used in this invention may include amino acid sequences and nucleotide sequences substantially identical sequences to sequences of the wild type human HGF isoforms. The substantial identity includes sequences with at least 80% identity, more preferably at least 90% identity and most preferably at least 95% identity as measured using one of the sequence comparison algorithms where the amino acid sequence or nucleotide sequence of the wild type human HGF isoform is aligned with a sequence in the maximal manner. Methods of alignment of sequences for comparison are well-known in the art. Various programs and alignment algorithms are described in: Smith and Waterman, Adv. Appl. Math. 2: 482 (1981); Needleman and Wunsch, J. Mol. Bio. 48: 443 (1970); Pearson and Lipman, Methods in Mol. Biol. 24: 307-31 (1988); Higgins and Sharp, Gene 73: 237-44 (1988); Higgins and Sharp, CABIOS 5: 151-3 (1989) Corpet et al., Nuc. Acids Res. 16: 10881-90 (1988); Huang et al., Comp. Appl. BioSci. 8: 155-65 (1992); and Pearson et al., Meth. Mol. Biol. 24: 307-31 (1994). The NCBI Basic Local Alignment Search Tool (BLAST) [Altschul et al., J. Mol. Biol. 215: 403-10 (1990)] is available from several sources, including the National Center for Biological Information (NBCl, Bethesda, Md.) and on the Internet, for use in connection with the sequence analysis programs blastp, blasm, blastx, tblastn and tblastx. BLAST can be accessed at http://www.ncbi.nlm.nih.gov/BLAST/. A description of how to determine sequence identity using this program is available at http://www.ncbi.nlm.nih.gov/BLAST/blast_help.html.

[0044] As used herein, the term "prevention" refers to all the acts of suppressing diabetic neuropathy or delaying the progress of diabetic neuropathy through administration of the composition of the present invention.

[0045] As used herein, the term "treatment" refers to (a) suppression of the development of diabetic neuropathy; (b) alleviation of diabetic neuropathy; and (c) removal of diabetic neuropathy.

[0046] About 15% of persons with diabetes show signs and symptoms of diabetic neuropathy, and among them, about 50% are found to have the traumatic damage of peripheral nerves on the electroneurography. Diabetic neuropathy is common among patients aged 50 or over, and various clinical subclass types are present. Pain is one of the common symptoms of diabetic neuropathy, and the frequency of pain varies depending on the patient.

[0047] According a preferable embodiment of the present invention, the composition of the present invention can prevent or treat diabetic neuropathy through the growth of neuronal cells or the suppression of neuronal cell death.

[0048] According to the present invention, when the PC12 neuronal cell line was treated with the isoforms f1HGF and dHGF, the cell growth effect was 50% and 70% higher than those in control groups treated with f1HGF and dHGF alone, respectively. In addition, when SH-SY5Y neuroblasts were treated with f1HGF and dHGF, the cell growth effect was 25% and 80% higher than those in control groups treated with the isoforms f1HGF and dHGF alone, respectively.

[0049] According to the present invention, when the PC12 neuronal cell line treated with high-concentration glucose was treated with the isoforms f1HGF and dHGF, the apoptosis of neuronal cells by glucose was reduced by about 2 fold, and the effect of inhibiting apoptosis of neuronal cells was about 1.5-fold higher than that in the control group treated with f1HGF.

[0050] According to the present invention, the safety of the isoforms of HGF and the pain reduction effects of the isoforms were confirmed through clinical trials in which the patients with diabetic neuropathy were injected with a polynucleotide expressing the isoforms f1HGF and dHGF. Therefore, the composition of the present invention is useful to the prevention and the treatment of diabetic neuropathy.

[0051] According to a preferable embodiment of the present invention, diabetic neuropathies of the present invention are largely classified into polyneuropathy and focal neuropathy.

[0052] According to a preferable embodiment of the present invention, the polyneuropathy of the present invention includes one or more diseases selected from the group consisting of hyperglycemic neuropathy, distal symmetric polyneuropathy, autonomic neuropathy, acute sensory neuropathy, acute painful sensory neuropathy, and chronic sensorimotor neuropathy, and the focal neuropathy of the present invention includes one or more diseases selected from the group consisting of cranial neuropathy, truncal neuropathy, limb neuropathy, thoracolumbar radiculoneuropathy, and lumbosacral radiculoplexus neuropathy. However, they are not limited thereto.

[0053] The composition of the present invention may be applied in vivo through various delivery methods conventionally known in the field of gene therapy.

[0054] According to a preferable embodiment of the present invention, the polynucleotide of the present invention is naked DNA or contained in a gene carrier. Examples of the gene carrier include plasmid, vector, and viral vector.

[0055] (i) Plasmid (Vector)

[0056] Plasmids (vectors) may be used as a gene carrier for the polynucleotide of the present invention.

[0057] It is preferred that the polynucleotide in vectors is contained in a suitable expression construct. According the expression construct, it is preferred that the polynucleotide is operatively linked to a promoter. The term "operatively linked" refers to functional linkage between a nucleic acid expression control sequence (such as a promoter, signal sequence, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence affects transcription and/or translation of the nucleic acid corresponding to the second sequence.

[0058] According to the present invention, the promoter linked to the polynucleotide is operable in, preferably, animal, more preferably, mammalian cells, to control transcription of the polynucleotide, including the promoters derived from the genome of mammalian cells or from mammalian viruses, for example, CMV (cytomegalovirus) promoter, the adenovirus late promoter, the vaccinia virus 7.5K promoter, SV40 promoter, HSV tk promoter, RSV promoter, EF1 alpha promoter, metallothionein promoter, beta-actin promoter, human IL-gene promoter, human IFN gene promoter, human IL-4 gene promoter, human lymphotoxin gene promoter and human GM-CSF gene promoter, but not limited to. More preferably, the promoter useful in this invention is a promoter derived from the IE (immediately early) gene of human CMV (hCMV) or EF1 alpha promoter, most preferably hCMV IE gene-derived promoter/enhancer and 5'-UTR (untranslated region) comprising the overall sequence of exon 1 and exon 2 sequence spanning a sequence immeidately before the ATG start codon.

[0059] The expression cassette used in this invention may comprise a polyadenylation sequence, for example, including bovine growth hormone terminator (Gimmi, E. R., et al., Nucleic Acids Res. 17:6983-6998 (1989)), SV40-derived polyadenylation sequence (Schek, N, et al., Mol. Cell Biol. 12:5386-5393 (1992)), HIV-1 polyA (Klasens, B. I. F., et al., Nucleic Acids Res. 26:1870-1876 (1998)), .beta.-globin polyA (Gil, A., et al, Cell 49:399-406 (1987)), HSV TK polyA (Cole, C. N. and T. P. Stacy, Mol. Cell. Biol. 5:2104-2113 (1985)) or polyoma virus polyA (Batt, D. B and G. G. Carmichael, Mol. Cell. Biol. 15:4783-4790 (1995)), but not limited to.

[0060] According to a preferable embodiment, the gene carrier for the polynucleotide includes pCK, pCP, pVAX1 and pCY vecors, more preferably pCK vector of which details are found in WO 2000/040737.

[0061] (ii) Retrovirus

[0062] Retroviruses capable of carrying relatively large exogenous genes have been used as viral gene delivery vectors in the senses that they integrate their genome into a host genome and have broad host spectrum.

[0063] In order to construct a retroviral vector, the polynucleotide of the invention is inserted into the viral genome in the place of certain viral sequences to produce a replication-defective virus. To produce virions, a packaging cell line containing the gag, pol and env genes but without the LTR (long terminal repeat) and .PSI. components is constructed (Mann et al., Cell, 33:153-159(1983)). When a recombinant plasmid containing the polynucleotide of the invention, LTR and .PSI. is introduced into this cell line, the .PSI. sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubinstein "Retroviral vectors," In: Vectors: A survey of molecular cloning vectors and their uses, Rodriguez and Denhardt (eds.), Stoneham: Butterworth, 494-513(1988)). The media containing the recombinant retroviruses is then collected, optionally concentrated and used for gene delivery.

[0064] A successful gene transfer using the second-generation retroviral vector has been reported. Kasahara et al. (Science, 266:1373-1376(1994)) prepared variants of moloney murine leukemia virus in which the EPO (erythropoietin) sequence is inserted in the place of the envelope region, consequently, producing chimeric proteins having novel binding properties. Likely, the present gene delivery system can be constructed in accordance with the construction strategies for the second-generation retroviral vector.

[0065] (iii) Adenovirus

[0066] Adenovirus has been usually employed as a gene delivery system because of its mid-sized genome, ease of manipulation, high titer, wide target-cell range, and high infectivity. Both ends of the viral genome contains 100-200 bp ITRs (inverted terminal repeats), which are cis elements necessary for viral DNA replication and packaging. The E1 region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome and a few cellular genes. The expression of the E2 region (E2A and E2B) results in the synthesis of the proteins for viral DNA replication.

[0067] Of adenoviral vectors developed so far, the replication incompetent adenovirus having the deleted E1 region is usually used. The deleted E3 region in adenoviral vectors may provide an insertion site for transgenes (Thimmappaya, B. et al., Cell, 31:543-551(1982); and Riordan, J. R. et al., Science, 245:1066-1073(1989)). Therefore, it is preferred that the decorin-encoding nucleotide sequence is inserted into either the deleted E1 region (E1A region and/or E1B region, preferably, E1B region) or the deleted E3 region. The polynucleotide of the invention may be inserted into the deleted E4 region. The term "deletion" with reference to viral genome sequences encompasses whole deletion and partial deletion as well. In nature, adenovirus can package approximately 105% of the wild-type genome, providing capacity for about 2 extra kb of DNA (Ghosh-Choudhury et al., EMBO J., 6:1733-1739(1987)). In this regard, the foreign sequences described above inserted into adenovirus may be further inserted into adenoviral wild-type genome.

[0068] The adenovirus may be of any of the 42 different known serotypes or subgroups A-F. Adenovirus type 5 of subgroup C is the most preferred starting material for constructing the adenoviral gene delivery system of this invention. A great deal of biochemical and genetic information about adenovirus type 5 is known. The foreign genes delivered by the adenoviral gene delivery system are episomal, and therefore, have low genotoxicity to host cells. Therefore, gene therapy using the adenoviral gene delivery system of this invention may be considerably safe.

[0069] (iv) AAV Vectors

[0070] Adeno-associated viruses are capable of infecting non-dividing cells and various types of cells, making them useful in constructing the gene delivery system of this invention. The detailed descriptions for use and preparation of AAV vector are found in U.S. Pat. Nos. 5,139,941 and 4,797,368.

[0071] Research results for AAV as gene delivery systems are disclosed in LaFace et al, Viology, 162:483486(1988), Zhou et al., Exp. Hematol. (NY), 21:928-933(1993), Walsh et al, J. Clin. Invest., 94:1440-1448(1994) and Flotte et al., Gene Therapy, 2:29-37(1995). Recently, an AAV vector has been approved for Phase I human trials for the treatment of cystic fibrosis.

[0072] Typically, a recombinant AAV virus is made by cotransfecting a plasmid containing the gene of interest (i.e., decorin gene and nucleotide sequence of interest to be delivered) flanked by the two AAV terminal repeats (McLaughlin et al., 1988; Samulski et al., 1989) and an expression plasmid containing the wild type AAV coding sequences without the terminal repeats (McCarty et al., J. Virol., 65:2936-2945(1991)).

[0073] (v) Other Viral Vectors

[0074] Other viral vectors may be employed as a gene delivery system in the present invention. Vectors derived from viruses such as vaccinia virus (Puhlmann M. et al., Human Gene Therapy 10:649-657(1999); Ridgeway, "Mammalian expression vectors," In: Vectors: A survey of molecular cloning vectors and their uses. Rodriguez and Denhardt, eds. Stoneham: Butterworth, 467-492(1988); Baichwal and Sugden, "Vectors for gene transfer derived from animal DNA viruses: Transient and stable expression of transferred genes," In: Kucherlapati R, ed. Gene transfer. New York: Plenum Press, 117-148(1986) and Coupar et al., Gene, 68:1-10(1988)), lentivirus (Wang G. et al., J. Clin. Invest. 104(11):R55-62(1999)) and herpes simplex virus (Chamber R., et al., Proc. Natl. Acad. Sci USA 92:1411-1415(1995)) may be used in the present delivery systems for transferring both the polynucleotide of the invention into cells.

[0075] (vi) Liposomes

[0076] Liposomes are formed spontaneously when phospholipids are suspended in an excess of aqueous medium. Liposome-mediated nucleic acid delivery has been very successful as described in Nicolau and Sene, Biochim. Biophys. Acta, 721:185-190(1982) and Nicolau et al., Methods Enzymol., 149:157-176(1987). Example of commercially accessible reagents for transfecting animal cells using liposomes includes Lipofectamine (Gibco BRL). Liposomes entrapping polynucleotide of the invention interact with cells by mechanism such as endocytosis, adsorption and fusion and then transfer the sequences into cells.

[0077] Where the gene delivery system is a naked recombinant DNA molecule or plasmid, the polynucleotide sequence of the invention is introduced into cells by microinjection (Capecchi, M. R., Cell, 22:479(1980) and Harland and Weintraub, J. Cell Biol. 101:1094-1099(1985)), calcium phosphate co-precipitation (Graham, F. L. et al., Virology, 52:456(1973) and Chen and Okayama, Mol. Cell. Biol. 7:2745-2752(1987)), electroporation (Neumann, E. et al., EMBO J., 1:841(1982) and Tur-Kaspa et al., Mol. Cell Biol., 6:716-718(1986)), liposome-mediated transfection (Wong, T. K. et al., Gene, 10:87(1980) and Nicolau and Sene, Biochim. Biophys. Acta, 721:185-190(1982); and Nicolau et al., Methods Enzymol., 149:157-176(1987)), DEAE-dextran treatment (Gopal, Mol. Cell Biol., 5:1188-1190(1985)), and particle bombardment (Yang et al., Proc. Natl. Acad. Sci., 87:9568-9572(1990)).

[0078] When the polynucleotide sequence of the present invention is constructed based on the viral vector, the polynucleotide sequence may be delivered into cells by various viral infection methods known in the art. The infection of host cells using viral vectors are described in the above-mentioned cited documents.

[0079] The pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier.

[0080] The pharmaceutically acceptable carrier may be conventional one for formulation, including lactose, dextrose, sucrose, sorbitol, mannitol, starch, rubber arable, potassium phosphate, arginate, gelatin, potassium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methyl cellulose, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, and mineral oils, but not limited to. The pharmaceutical composition according to the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, and a preservative. Details of suitable pharmaceutically acceptable carriers and formulations can be found in Remington's Pharmaceutical Sciences (19th ed., 1995), which is incorporated herein by reference.

[0081] Preferably, the pharmaceutical composition of this invention may be administered parenterally. For non-oral administration, intravenous injection, intraperitoneal injection, intramuscular injection, subcutaneous injection, or local injection may be employed. For example, the pharmaceutical composition may be injected by retrograde intravenous injection.

[0082] Preferably, the pharmaceutical composition of the present invention may be administered into the muscle, and more preferably into the calf muscle.

[0083] A suitable dosage amount of the pharmaceutical composition of the present invention may vary depending on pharmaceutical formulation methods, administration methods, the patient's age, body weight, sex, pathogenic state, diet, administration time, administration route, an excretion rate and sensitivity for a used pharmaceutical composition, and physicians of ordinary skill in the art can determine an effective amount of the pharmaceutical composition for desired treatment.

[0084] According to a preferable embodiment of the present invention, the isoforms of HGF of the present invention are administered at a dose of 1 .mu.g to 100 mg for each, and the polynucleotide encoding the isoforms is administered at a dose of 1 .mu.g to 40 mg. When the isoforms of HGF or the polynucleotide encoding the isoforms is repeatedly administered once or more, the dose may be equal or different for each administration.

[0085] According to the conventional techniques known to those skilled in the art, the pharmaceutical composition may be formulated with pharmaceutically acceptable carrier and/or vehicle as described above, finally providing several forms a unit dose form and a multi-dose form. Non-limiting examples of the formulations include, but not limited to, a solution, a suspension or an emulsion in oil or aqueous medium, an extract, an elixir, a powder, a granule, a tablet and a capsule, and may further comprise a dispersion agent or a stabilizer.

Advantageous Effects

[0086] Features and advantages of the present invention are summarized as follows:

[0087] (a) The pharmaceutical composition of the present invention for preventing or treating diabetic neuropathy contains, as active ingredients, different types of isoforms of HGF or at least one polynucleotide encoding the isoforms.

[0088] (b) The present invention first established that the use of different types of isoforms of HGF or at least one polynucleotide expressing the isomers can treat diabetic neuropathy more effectively than the use of the full-length HGF.

[0089] (c) According to the present invention, diabetic neuropathy can be treated very effectively.

BRIEF DESCRIPTION OF THE DRAWINGS

[0090] FIG. 1 is a diagram showing a procedure for constructing pVAX1-cHGF.

[0091] FIG. 2 is a diagram showing a procedure for constructing pVAX1-HGF-X7.

[0092] FIG. 3 is a diagram showing a procedure for constructing pCY-cHGF and pCY-dHGF.

[0093] FIG. 4 is a diagram showing a procedure for constructing pCY-HGF-X3, pCY-HGF-X4, pCY-HGF-X7, and pCY-HGF-X8.

[0094] FIG. 5 is a diagram showing a procedure for constructing pCY-HGF-X2 and pCY-HGF-X6.

[0095] FIG. 6 is a diagram showing a procedure for constructing pCY-HGF-X5.

[0096] FIG. 7 shows results of RNA expression of respective isoforms of HGF.

[0097] FIG. 8 shows results of protein expression of respective isoforms of HGF.

[0098] FIG. 9 shows effects of isoforms of HGF on the growth of PC12 cells.

[0099] FIG. 10 shows an effect of pCK-HGF-X7 on the growth of PC12 cells.

[0100] FIG. 11 shows an effect of pCK-HGF-X7 on the growth of SH-SY5Y cells.

[0101] FIG. 12 shows an effect of pCK-HGF-X7 on PC12 cells that are growth-inhibited by high-concentration glucose.

[0102] FIG. 13 shows an effect of pCK-HGF-X7 on apoptosis of PC12 cells, induced by high-concentration glucose.

[0103] FIG. 14 is a diagram illustrating the visual analogue scale (VAS) estimation.

[0104] FIG. 15 shows results of pharmacodynamics of pCK-HGF-X7.

[0105] FIG. 16 shows results of efficacy of pCK-HGF-X7.

[0106] FIG. 17 shows results of efficacy of pCK-HGF-X7 in a first dose group (4 mg).

[0107] FIG. 18 shows results of efficacy of pCK-HGF-X7 in a second dose group (8 mg).

[0108] FIG. 19 shows results of efficacy of pCK-HGF-X7 in a third dose group (16 mg).

[0109] FIG. 20 shows the comparison of VAS among three dose groups (4 mg, 8 mg, and 16 mg).

MODE FOR CARRYING OUT THE INVENTION

[0110] The present invention will now be described in further detail by examples. It would be obvious to those skilled in the art that these examples are intended to be more concretely illustrative and the scope of the present invention as set forth in the appended claims is not limited to or by the examples.

EXAMPLES

Example 1: Preparation of Plasmid DNA Expressing Isoforms of HGF

[0111] In order to carry out the following various experiments, the present inventors used the pCK vector as a vector capable of expressing isoforms of HGF. The pCK vector is constructed such that the expression of a subject to be expressed, e.g., an HGF gene, is regulated under enhancer/promoter of the human cytomegalovirus (HCMV), and is disclosed in detail in Lee et al., Biochem. Biophys. Res. Commun. 272:230 (2000); WO 2000/040737. Currently, the pCk vector is used for clinical trials on human body, and its safety and efficacy were confirmed (Henry et al., Gene Ther. 18:788 (2011)). In order to prepare plasmid DNAs expressing hybrid HGF genes as a therapeutic agent for diabetic neuropathy, the present inventors inserted each of the hybrid HGF genes into the pCK vector according to the method disclosed in U.S. Pat. No. 7,812,146.

Example 2: Verification of Hybrid HGF Genes Co-Expressing Isoforms of HGF

[0112] 2-1. Construction of Vector Expressing Isoforms of HGF

[0113] In order to verify the expression of isoforms of HGF, gene expression vectors for cHGF (f1HGF), dHGF, and a hybrid form thereof were prepared, and the HGF gene expressing vector was compared with the cHGF or dHGF expressing vector. The cHGF obtained by treating the pCK-cHGF disclosed in U.S. Pat. No. 7,812,146 with BamHI was inserted into the BamHI site of the pVAX1 (Invitrogen, USA) to construct pVAX1-cHGF (FIG. 1). The HGF-X7 obtained by treating the pCP-HGF-X7 with Nhel and Apal was inserted into the pVAX1 treated with the same enzymes to construct pVAX1-HGF-X7 (FIG. 2).

[0114] The promoter obtained by treating the pVAX1-cHGF with NdeI and BstEII was inserted into the pCK-cHGF and pCK-dHGF without promoters, respectively, which were obtained by treatment with the same enzymes, to construct new plasmids, pCY-cHGF and pCY-dHGF, using the term pCY, respectively (FIG. 3). The pVAX1-HGF-X7 was treated with NdeI and BstEII to obtain a promoter, which was then inserted into the pCK-HGF-X3, pCK-HGF-X4, pCK-HGF-X7, and pCK-HGF-X8 without promoters, respectively, which were obtained by treatment with the same enzymes, to construct pCY-HGF-X3, pCY-HGF-X4, pCY-HGF-X7, and pCY-HGF-X8, respectively (FIG. 4). The pCY-HGF-X7 was treated with SpeI and BstEII to obtain a promoter, which was then inserted into the pCK-HGF-X2 and pCK-HGF-X6 without promoters, respectively, which were obtained by treatment with the same enzymes, to construct pCY-HGF-X2 and pCY-HGF-X6, respectively (FIG. 5). The pCY-HGF-X7 was treated with SnaBI and NheI to obtain a promoter, which was then inserted into the pCK-HGF-X5 without promoters, which was obtained by treatment with the same enzymes, to construct pCY-HGF-X5 (FIG. 6).

[0115] 2-2. Verification of RNA Expression of Isoforms of HGF

[0116] Each of the plasmid DNAs was transfected into 1.times.10.sup.6 cells of 293T cells (ATCC CRL 1573) using FuGENE6 (Roche, USA) according to the manufacturer's instructions. At 48 hours after transfection, cells for each of the plasmids were harvested. RNA was extracted from the harvested 293T cells using the Trizol method (Trizol; Invitrogen, USA), and subjected to RT-PCR to obtain cDNA. PCR was conducted using the harvested cDNA as a template DNA and synthetic oligonucleotides of SEQ ID NO: 15 and SEQ ID NO: 16 as a primer pair. The PCR was conducted such that 3 .mu.l of the template DNA, 1 .mu.l each of 10 pmol/.mu.l primer, 5 .mu.l of 2.5 mM dNTP, 3.5 units of High fidelity enzyme mix (Roche, USA), and 5 .mu.l of an enzyme buffer solution were mixed to prepare a total of 50 .mu.l of a mixture liquid, which was then subjected to PCR amplification under conditions of 40 cycles of 30 seconds at 95.degree., 30 seconds at 60.degree., and 30 seconds at 72.degree.. The thus amplified PCR products correspond to the boundary region between exon 4 and exon 5 of the HGF gene. Here, the nucleotide sequence of 142 bp is amplified for cHGF cDNA and the nucleotide sequence of 127 bp is amplified for dHGF cDNA.

[0117] As for the HGF-X gene, nucleotide sequences of at least 1 kb are amplified when the splicing does not occur, and both of the nucleotide sequences of 142 bp and 127 bp are amplified when alternative splicing occurs and thus cHGF and dHGF simultaneously are produced. The amplified PCR products were confirmed by electrophoresis on 15% polyacrylamide gels. As a result, the bands of 142 bp and 127 bp were detected for cHGF cDNA and dHGF cDNA, respectively, and both bands of 142 bp and 127 bp were detected for the hybrid HGF (FIG. 7).

[0118] 2-3. Verification of Protein Expression of Isoforms of HGF

[0119] Each of the plasmid DNAs was transfected into 1.times.10.sup.6 cells of 293T cells (ATCC CRL 1573) using FuGENE6 (Roche, USA) according to the manufacturer's instructions. At 48 hours after transfection, the supernatant of each of the plasmid DNAs was harvested. The amount of HGF protein in the supernatant was measured using an enzyme-linked immunosorbent assay (ELIS; R&D System, MN, USA). As a result, it was verified that, among the hybrid HGF genes, HGF-X7 showed the highest protein expression level.

Example 3: Effect of Hybrid HGF Expressed in pCK Vector on Growth and Survival of Neuronal Cells

[0120] 3-1. Effect of Hybrid HGF on Growth of Neuronal Cells

[0121] (1) Cell Line and Cell Culture

[0122] Rat-derived P12 pheochromocytoma (CRL-1721; ATCC, MD, USA) was used in this experiment. P12 cells are commonly used in the research of diabetic neuropathy. It has been recently validated that glucose reduces neuritis of PC12 cells (Fan Zhang et al., THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 323:508-515 (2007)). In addition, it has been reported that glucose induces the reduction in proliferation of PC12 cells and DNA disruption, resulting in apoptosis of PC12 cells (EFRAT LELKES et al., Neurotoxicity research. 3:189-203 (2000)). PC12 cells were cultured in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 15% fetal bovine serum and antibiotics under 37.degree. and 5% CO.sub.2. The cell culture medium, reagent, and serum were purchased from Gibco (Gibco BRL life technologies, inc., MD, USA), and plastic products for culture were purchased from BD Falcon (BD Falcon, NJ, USA).

[0123] (2) Preparation of Supernatants Containing Hybrid HGF Proteins and Recombinant Human HGF Protein

[0124] Supernatants expressing hybrid HGF proteins, that is, HGF-X2, HGF-X3, HGF-X4, HGF-X5, HGF-X6, HGF-X7, and HGF-X8 were produced using DNA transfection. The transfection was conducted by using the Cellphect phosphate calcium transfection system (GE Healthcare BioSciences, NJ, USA) according to the manufacture's protocol. 293T cell lines seeded at 1.times.10.sup.6 cells per well one day before were transfected with pCK, pCK-HGF-X2, pCK-HGF-X3, pCK-HGF-X4, pCK-HGF-X5, pCK-HGF-X6, pCK-HGF-X7, and pCK-HGF-X8, and then the cells were incubated for 48 hours. Upon the completion of culturing, the supernatants were all harvested, and then filtered through a 0.22-.mu.m filter. The harvested protein supernatants were frozen at -80.degree. before use.

[0125] Recombinant human HGF protein was purchased from R&D (R&D Systems, Inc., MSP, USA) for use.

[0126] (3) Verification of Protein Expression and Protein Quantification

[0127] In order to verify the expression of the respective proteins in the supernatants of 293T cells, the human HGF immunoassay by R&D (R&D Systems, Inc., MSP, USA) was used. The expression levels of the respective proteins were measured, and then the respective supernatants were again diluted to 1 .mu.g/ml for the use of experiments.

[0128] (4) Comparison of Cell Growth Among Hybrid HGF Proteins in PC12 Cells

[0129] In order to compare effects of hybrid HGF proteins on the growth of neuronal cells, the following experiment was conducted using PC12 cells. PC12 cells were seeded in a 6-well plate at 1.times.10.sup.5 cells per well, and the next day, the medium was exchanged with a medium containing 1% FBS. The 293T cell supernatant expressing each protein was added thereto at a concentration of 5 ng/ml, followed by culturing for 7 days, and then cell counting was conducted. As control groups, the supernatant of 293T cells transfected with the pCK vector and the recombinant human HGF protein were used. As a result, all the experiment groups added with the supernatants expressing all the hybrid HGF proteins excluding HGF-X4 were observed to exhibit higher cell growth than the control groups. The experiment groups added with the supernatants expressing HGF-X6, HGF-X7, and HGF-X8 showed statistically significant differences as compared with the control group (pCK vector) (P<0.05 or P<0.005; FIG. 9).

[0130] Since the pCK-HGF-X7 showed the highest gene expression level among the hybrid HGF genes (see, FIG. 8) and the distinctive statistical significance (P<0.005) in the growth of PC12 cells, the pCK-HGF-X7 was used in the following experiments and clinical trials.

[0131] 3-2. Comparison Between Effects of HGF-X7 and cHGF on Growth of Neuronal Cells

[0132] (1) Cell Line and Cell Culture

[0133] Cell lines used in the present experiment were a total of two, PC12 cell line and human-derived SH-SY5Y neuroblasts (22266; KCLB, Korea). The SH-SY5Y cell line, like the PC12 cell line, is one of the most used cell lines for research of diabetic neuropathy. According to the study on diabetic neuropathy using SH-SY5Y cells, it has been known that glucose increases the depolarization of mitochondrial membranes of the SH-SY5Y cells and activates inactivated caspase-3, leading to apoptosis of the SH-SY5Y cells (G M Leinninger et al., Cell Death and Differentiation.11:885-896 (2004)). All the cells were cultured under conditions of 37.degree. and 5% CO.sub.2. The PC12 cells were cultured in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 15% fetal bovine serum and antibiotics, and the SH-SY5Y cells were cultured in Minimum Essential Medium (MEM) supplemented with 10% fetal bovine serum and antibiotics. The cell culture medium, reagent, and serum were purchased from Gibco and the ATCC (American Type Culture Collection, MD, USA).

[0134] (2) Production and Quantification of Supernatants Expressing HGF Proteins

[0135] 293T cells were seeded at 1.times.10.sup.6 cells, and the next day, the cells were transfected with pCK, pCK-cHGF, pCK-dHGF, and pCK-HGF-X7. After culturing for 48 hours, the supernatants were all harvested, and then filtered through a 0.22-.mu.m filter. The expression levels of the HGF proteins contained in the respective supernatants were measured using human HGF immunoassay. The respective supernatants were again diluted to 1 .mu.g/ml for the use of experiments.

[0136] (3) Comparison Between Growths of PC12 Cells by HGF-X7 and cHGF

[0137] In order to compare effects on the growth of neuronal cells, the cell proliferation degrees by the respective proteins were evaluated using PC12 cells. For achieving this, PC12 cells were seeded in a 6-well plate at 1.times.10.sup.5 cells per well, and the next day, the medium was exchanged with a medium containing FBS. The respective proteins obtained from 293T cells transfected with pCK, pCK-cHGF, pCK-dHGF, and pCK-HGF-X7 were added thereto at concentrations of 5 ng/ml. The pCK vector was used for a control group.

[0138] As a result of cell counting after culturing for 7 days, the experiment group added with the supernatant of 293T cells containing HGF-X7 was verified to have the highest cell number. The experiment group added with HGF-X7 showed a cell growth effect, which was about 50% higher than that in cHGF and about 70% higher than that in dHGF (FIG. 10).

[0139] (4) Comparison Between Cell Growths of SH-SY5Y Cells by HGF-X7 and cHGF

[0140] In order to compare effects on the growth of neuronal cells, SH-SY5Y cells, the cell proliferation degrees by the respective proteins were measured. For achieving this, SH-SY5Y cell line was seeded in a 6-well plate at 5.times.10.sup.4 cells per well. The next day, the medium was exchanged with a medium containing 1% FBS. The respective proteins obtained from 293T cells transfected with pCK, pCK-cHGF, pCK-dHGF, and pCK-HGF-X7 were added thereto at concentrations of 5 ng/ml. The pCK vector was used for a control group.

[0141] As a result of cell counting after culturing for 7 days, the experiment group added with the supernatant of 293T cells containing HGF-X7 was verified to have the highest cell number. The experiment group added with HGF-X7 showed a cell growth effect, which was about 25% higher than that in cHGF and about 80% higher than that in dHGF (FIG. 11).

[0142] 3-3. Effect of HGF-X7 on Growth of PC12 Cells in Culture Conditions of High-Concentration Glucose

[0143] (1) Selection of Glucose Concentration and Culture Time for Inhibition of Growth of PC12 Cells

[0144] Prior to the verification of an effect of HGF-X7 on the growth of PC12 cells under the culture conditions of high-concentration glucose, the glucose concentration and the culture time for inhibiting the growth of PC12 cells were selected. PC12 cells were seeded in a 96-well plate at 5.times.10.sup.4 cells per well, and the next day, the medium was exchanged with 100 mM and 200 mM glucose media containing 1% FBS, respectively. As a control group, a medium containing 50 mM glucose, which was a culture medium of PC12 cells, was used. At 24, 48, and 72 hours after medium exchange, the cell growth was measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, WI, USA). The growth of PC12 cells was verified to be reduced in the high-concentration glucose medium. In particular, the growth of PC12 cells was observed to be reduced by about 50% in the 200 mM glucose medium at 48 hours and 72 hours. Based on these results, the glucose concentration and the culture time for inhibiting the growth of PC12 cells were selected to be 200 mM and 72 hours, respectively.

[0145] (2) Verification of Effect of HGF-X7 on Growth of PC12 Cells in Culture Conditions of High-Concentration Glucose

[0146] The effect of HGF-X7 on the growth of PC12 cells in the culture conditions of high-concentration glucose was confirmed. PC12 cell line was seeded in a 96-well plate at 5.times.10.sup.4 cells per well. The next day, the medium was exchanged with a 200 mM glucose medium, and then 50 ng/ml of the 293T cell supernatant expressing HGF-X7 was added thereto.

[0147] As a result of confirming the cell growth after culturing for 72 hours, it was observed that the experiment group added with the supernatant expressing HGF-X7 showed an increase by about 23% or more in cell growth as compared with the control group (pCK vector), and an increase by about 10% or more in cell growth as compared with the experiment group added with the same concentration of the supernatant containing cHGF.

[0148] 3-4. Effect of HGF-X7 on Apoptosis Inhibitory Effect of PC12 Cells Under the Culture Conditions of High-Concentration Glucose

[0149] (1) Selection of Glucose Concentration and Culturing Time for Inducing Apoptosis of PC12 Cells

[0150] Prior to the estimation of an effect of HGF-X7 on apoptosis of PC12 cells under the culture conditions of high-concentration glucose, the glucose concentration and the culture time for inducing apoptosis of PC12 cells were selected. The PC12 cell line was seeded in a 6-well plate at 1.times.10.sup.5 cells per well, and the next day, the medium for the PC12 cell line was exchanged with 50 mM, 100, mM, and 200 mM glucose media containing 1% FBS. The cells were cultured for 48 hours or 72 hours, and then all the cells were collected. The supernatants were removed by centrifugation for 3 minutes at 12000 rpm, followed by washing with PBS. This procedure was repeated once more. The degrees of apoptosis for the collected cells were measured using the Annexin V apoptosis assay system (BD Biosciences, NJ, USA). A 1.times. Annexin V binding buffer was put into the collected cells at a volume of 1 ml per 1.times.10.sup.6 cells, so that the cells were suspended in the buffer. 5 .mu.l of Annexin-V and a propidium iodide buffer were added to 100 .mu.l of the suspended cells to stain the suspended cells for 20 minutes in the dark. 400 .mu.l of a 1.times. Annexin V binding buffer was further added to the stained cells to detect apoptosis by flow cytometry.

[0151] As a result, the apoptosis of PC12 cells was not induced when the cells were cultured in the 100 mM glucose medium for 48 hours, as compared with the control group, but about 2.5-fold of apoptosis was induced in the 200 mM glucose medium as compared with the control group. Whereas, it was verified that, under the culture conditions for 72 hours, the apoptosis was induced in both 100 mM and 200 mM glucose media as compared with the control group, and the significant difference between 100 mM and 200 mM glucose media was not shown. Based on these results, the glucose concentration and the culture time for inducing apoptosis of PC12 cells were selected to be 200 mM and 48 hr, respectively.

[0152] (2) Effect of HGF-X7 on Apoptosis of PC12 Cells in Culture Conditions of High-Concentration Glucose

[0153] The PC12 cell line was seeded in a 6-well plate at seeded in at 1.times.10.sup.5 cells per well, and the next day, the medium for the PC12 cell line was exchanged with 200 mM glucose medium containing 1% FBS. 50 ng/10 of the 293T cell supernatant expressing cHGF or HGF-X7 was added thereto. As a control group, the supernatant of 293T cells transfected with the pCK vector was used. After culturing for 48 hours, all the cells were collected. Staining was conducted using the Annexin V apoptosis assay system, and then the degrees of apoptosis were confirmed by flow cytometry.

[0154] As a result, the experiment group added with the 293T cell supernatant expressing HGF-X7 was verified to lead to a 2-fold decrease in apoptosis as compared with the control group added with the 293T cell supernatant expressing the pCK vector and show an apoptosis inhibitory effect of about 1.5 times or higher as compared with the experiment group added with the supernatant containing cHGF (FIG. 13).

Example 4: Clinical Trial of pCK-HGF-X7 Against Diabetic Neuropathy

[0155] 4-1. Subjects and Administration

[0156] A phase I clinical trial for safety and efficacy of pCK-HGF-X7 was conducted for 12 patients diagnosed with diabetic neuropathy. The time and dose of administration were different for three trial groups as shown in Table 1.

TABLE-US-00001 TABLE 1 Number of times Trial Dose of of administration Total dose of group administration Day 0 Day 14 administration I 4 mg 8 8 8 m II 8 mg 16 16 16 m III 16 mg 32 32 32 m

[0157] 4-2. Methods

[0158] (1) Informed Consent Form and Screening Procedure

[0159] After receiving informed consent forms from patients, a screening procedure for checking the possibility of participating in the present clinical trial was conducted. The screening procedure was conducted within 30 days before day 0 of primary administration, and the possibility of participating in the present clinical trial was determined for each of the patients based on the following items.

[0160] a. complete medical history

[0161] b. complete physical exam

[0162] c. cancer screening tests

[0163] d. retinal fundoscopy

[0164] e. viral screening tests

[0165] f. hematology and serum chemistry

[0166] g. urinalysis

[0167] h. urine pregnancy test (for only females)

[0168] i. Ulcer screening (if possible)

[0169] j. ECG

[0170] k. Michigan Neuropathy Screening Instrument

[0171] l. Visual Analogue Scale

[0172] (2) Administration of Trial Drug

[0173] The pCK-HGF-X7 was injected in the right calf muscle of each of the subjects undergoing screening at an interval of two weeks (Day 0 and Day 14). The subjects assigned to trial group I were administered with 2 mg of pCK-HGF-X7 on Day 0, and again administered with 2 mg of pCK-HGF-X7 on Day 14. Therefore, trial group I was administered with a total of 4 mg of pCK-HGF-X7. On Day 0, each of the subjects was administered with 2 mg of pCK-HGF-X7, which was injected in eight sites of the calf muscle at a divided dose of 0.25 mg/0.5 ml/site. On Day 14, the administration was also conducted in the same manner. Trial group II was administered with a total of 8 mg of pCK-HGF-X7 (4 mg on Day 0 and 4 mg on Day 14). The administration was conducted similarly to trial group I. That is, on Day 0, each of the subjects of trial group II was administered with 4 mg of pCK-HGF-X7, which was injected in 16 sites of the calf muscle at a divided dose of 0.25 mg/0.5 ml/site. On Day 14, the administration was conducted in the same manner. Trial group III was administered with a total of 16 mg of pCK-HGF-X7 (8 mg on Day 0 and 8 mg on Day 14). On Day 0, each of the subjects of trial group III was administered with 8 mg of pCK-HGF-X7, which was injected in 32 sites of the calf muscle at a divided dose of 0.25 mg/0.5 ml/site. On Day 14, the injection in 32 sites was conducted in the same manner.

[0174] 4-3. Clinical Evaluation Indicator

[0175] The primary endpoint of the present clinical trial is to confirm the safety of pCK-HGF-X7 injected in the calf muscle of each of the patients with diabetic neuropathy, and the secondary endpoint of the present clinical trial is to confirm the efficacy of pCK-HGF-X7 on pain, which is a main symptom of diabetic neuropathy.

[0176] (1) Safety Analysis

[0177] All the subjects administered with the trial drug in the present clinical trial are to be tested for safety analysis. Through follow-up observation of 12 months after administration, adverse event data (including adverse events and adverse events to stop administration of trial drug) were all recorded according to the extents thereof and relations with the trial drug. If possible, safety analysis was conducted through all statistical analysis. In addition, in order to avoid risks associated with cancers, all the subjects were screened by the method specified in the American Cancer Society Cancer Screening Guideline during the screening procedure.

[0178] (2) Pharmacokinetic Analysis

[0179] The level of HGF protein in serum of the subject and the amount of pCK-HGF-X7 in blood of the subject were measured before and after the administration of the trial drug of Day 0, and before and after the administration of the trial drug of Day 14, on Day 21, on Day 30, on Day 60, and on Day 90.

[0180] (3) Efficacy Analysis

[0181] A visual analogue scale (VAS) method was used to record the change in pain for all the subjects. According to the VAS method, the individual preference for a health state was directly measured. That is, each of the subjects is allowed to directly score a scale for the severity of pain. A 100 mm-long line was drawn, and "No pain at all" was marked at one side of the line and "Pain as bad as it can be" was marked at the other side of the line. Then, the subjects are allowed to determine and record the severity of pain by themselves according to the VAS indicator. This method cannot show the comparison between different subjects, but can show the change in the severity of pain for the same subject (FIG. 14). In order to deduce clinically significant results, the safety analysis was conducted through every possible statistical analysis.

[0182] 4-4. Results

[0183] (1) Safety Results (Adverse Event Report)

[0184] As for the adverse events due to administration of pCK-HGF-X7 of the present invention, seven adverse events occurred in a total of three subjects of trial group I; two adverse events occurred in two subjects of trial group II; and two adverse events occurred in two subjects of trial group III. The adverse events were reported to be dry eyes, injection site pain, dry mouth, diarrhea, and the like in trial group I; back pain and sinusitis in trial group II; and right rib pain and viral syndrome in trial group III. The number of adverse drug events was five, which were reported in two subjects of trial group I, dry eyes (two events), injection site pain, dry mouth, and diarrhea, but they correspond to mild adverse drug events and thus recovered soon. Whereas, no serious adverse events were reported.

[0185] (2) Pharmacodynamics (PD) Results

[0186] As a result of confirming the amount of HGF protein produced in serum after administration of pCK-HGF-X7, it was verified that the level of HGF protein in serum after administration of pCK-HGF-X7 was not increased but maintained during the clinical trial (FIG. 15).

[0187] (3) Pharmacokinetics (PK) Results

[0188] As a result of confirming the amount of pCK-HGF-X7 remaining after pCK-HGF-X7 treatment, the pCK-HGF-X7 DNA was not detected in ten subjects during follow-up observation of 60 days, and was detected at under 100 copies/ml for all the subjects (Table 2).

TABLE-US-00002 TABLE 2 Day 0 Day 14 Trial Patient Prior Post Prior Post Day Day Day Day group ID administration administration administration administration 21 30 60 90 I 1-01 NEG 45846.3 NEG 62,762.8 10.0 7.1 NEG NEG 2-01 NEG 38401.5 NEG 18,215.9 NEG NEG NEG NEG 2-02 NEG 5871.8 NEG 38,401.5 NEG NEG NEG NEG 2-03 NEG 18215.9 NEG 5,871.8 NEG NEG NEG NEG II 2-04 NEG 562,669.0 NEG 300,852.0 51.0 NEG 38.1 NEG 1-02 NEG 114,319.0 333.0 139,297.0 56,266.9 219.0 91.1 NEG 2-05 NEG 183,514.0 63.0 582,978.0 3,875.0 69.0 NEG 28.9 1-03 5.1 177,131.0 319.0 1,532,729.0 262.8 108.1 NEG NEG III 1-04 NEG 1,920,770.8 148 6,252,606.8 1,637.5 162.2 NEG 42.7 2-07 NEG 368,173.0 NEG 23,198.3 32.9 NEG NEG NEG 2-08 NEG 76,888.4 170.7 101,424.0 157.6 58.6 50.6 NEG 2-09 NEG 491,690.2 77.1 432,454.6 77.6 33.7 NEG NEG

[0189] (4) Efficacy Test Results

[0190] The severity of pain was measured through the Pain VAS (Visual Analogue Scale). As for a total of twelve subjects, the mean baseline VAS value was 48.0, and the mean VAS value at six months after the pCK-HGF-X7 treatment was 25.4, which showed a 47% reduction in the pain VAS value (FIG. 16).

[0191] In the case of the first dose group (4 mg), the mean baseline VAS value was 39.5, and the mean VAS value at two months after treatment was 23.8, which showed a 39.7% reduction in the pain VAS value, but the mean VAS value at six months after treatment was 31.3, which merely showed a 20.8% reduction in the pain VAS value as compared with the baseline value. In the first dose group, the pain reduction was observed in three of four subjects and the pain reduction of 50% or higher was observed in two of four subjects (FIG. 17).

[0192] In the case of the second dose group (8 mg), the mean baseline VAS value was 59.1, and the VAS value from one month after treatment was sharply reduced and the mean VAS value at six months after treatment was 27.5, which showed a 53.5% reduction in the pain VAS value as compared with the baseline value (FIG. 18).

[0193] In the case of the third dose group (16 mg), the mean baseline VAS value was 45.3. Similarly to the second dose group, the VAS value from one month after treatment was sharply reduced and the mean VAS value at six months after treatment was 17.3, which showed a 61.4% reduction in the pain VAS value as compared with the baseline value. In the third dose group, the pain reduction was observed in all four subjects and the pain reduction of 50% or higher was observed in three of four subjects (FIG. 19).

[0194] As a result of surveying the efficacy using the pain VAS, the pain, which is the main symptom of diabetic neuropathy, was reduced after the pCK-HGF-X7 injection, and the pain reduction rate and the response rate to pain reduction were more remarkable in the medium-dose group (8 mg) or the high-dose group (16 mg) than in the low-dose group (4 mg). These results supported that the pain reduction observed in the present clinical trial was due to the administration of pCK-HGF-X7 and not the placebo effect (FIG. 20).

[0195] Having described a preferred embodiment of the present invention, it is to be understood that variants and modifications thereof falling within the spirit of the invention may become apparent to those skilled in this art, and the scope of this invention is to be determined by appended claims and their equivalents.

Sequence CWU 1

1

161728PRTArtificial Sequenceamino acid sequence of flHGF 1Met Trp Val Thr Lys Leu Leu Pro Ala Leu Leu Leu Gln His Val Leu 1 5 10 15 Leu His Leu Leu Leu Leu Pro Ile Ala Ile Pro Tyr Ala Glu Gly Gln 20 25 30 Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys Thr 35 40 45 Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys Lys Val 50 55 60 Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly Leu 65 70 75 80 Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys Gln Cys 85 90 95 Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu Phe 100 105 110 Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn Cys 115 120 125 Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val Ser Ile Thr Lys 130 135 140 Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu His 145 150 155 160 Ser Phe Leu Pro Ser Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn Tyr 165 170 175 Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp Cys Phe Thr Ser 180 185 190 Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser Glu 195 200 205 Val Glu Cys Met Thr Cys Asn Gly Glu Ser Tyr Arg Gly Leu Met Asp 210 215 220 His Thr Glu Ser Gly Lys Ile Cys Gln Arg Trp Asp His Gln Thr Pro 225 230 235 240 His Arg His Lys Phe Leu Pro Glu Arg Tyr Pro Asp Lys Gly Phe Asp 245 250 255 Asp Asn Tyr Cys Arg Asn Pro Asp Gly Gln Pro Arg Pro Trp Cys Tyr 260 265 270 Thr Leu Asp Pro His Thr Arg Trp Glu Tyr Cys Ala Ile Lys Thr Cys 275 280 285 Ala Asp Asn Thr Met Asn Asp Thr Asp Val Pro Leu Glu Thr Thr Glu 290 295 300 Cys Ile Gln Gly Gln Gly Glu Gly Tyr Arg Gly Thr Val Asn Thr Ile 305 310 315 320 Trp Asn Gly Ile Pro Cys Gln Arg Trp Asp Ser Gln Tyr Pro His Glu 325 330 335 His Asp Met Thr Pro Glu Asn Phe Lys Cys Lys Asp Leu Arg Glu Asn 340 345 350 Tyr Cys Arg Asn Pro Asp Gly Ser Glu Ser Pro Trp Cys Phe Thr Thr 355 360 365 Asp Pro Asn Ile Arg Val Gly Tyr Cys Ser Gln Ile Pro Asn Cys Asp 370 375 380 Met Ser His Gly Gln Asp Cys Tyr Arg Gly Asn Gly Lys Asn Tyr Met 385 390 395 400 Gly Asn Leu Ser Gln Thr Arg Ser Gly Leu Thr Cys Ser Met Trp Asp 405 410 415 Lys Asn Met Glu Asp Leu His Arg His Ile Phe Trp Glu Pro Asp Ala 420 425 430 Ser Lys Leu Asn Glu Asn Tyr Cys Arg Asn Pro Asp Asp Asp Ala His 435 440 445 Gly Pro Trp Cys Tyr Thr Gly Asn Pro Leu Ile Pro Trp Asp Tyr Cys 450 455 460 Pro Ile Ser Arg Cys Glu Gly Asp Thr Thr Pro Thr Ile Val Asn Leu 465 470 475 480 Asp His Pro Val Ile Ser Cys Ala Lys Thr Lys Gln Leu Arg Val Val 485 490 495 Asn Gly Ile Pro Thr Arg Thr Asn Ile Gly Trp Met Val Ser Leu Arg 500 505 510 Tyr Arg Asn Lys His Ile Cys Gly Gly Ser Leu Ile Lys Glu Ser Trp 515 520 525 Val Leu Thr Ala Arg Gln Cys Phe Pro Ser Arg Asp Leu Lys Asp Tyr 530 535 540 Glu Ala Trp Leu Gly Ile His Asp Val His Gly Arg Gly Asp Glu Lys 545 550 555 560 Cys Lys Gln Val Leu Asn Val Ser Gln Leu Val Tyr Gly Pro Glu Gly 565 570 575 Ser Asp Leu Val Leu Met Lys Leu Ala Arg Pro Ala Val Leu Asp Asp 580 585 590 Phe Val Ser Thr Ile Asp Leu Pro Asn Tyr Gly Cys Thr Ile Pro Glu 595 600 605 Lys Thr Ser Cys Ser Val Tyr Gly Trp Gly Tyr Thr Gly Leu Ile Asn 610 615 620 Tyr Asp Gly Leu Leu Arg Val Ala His Leu Tyr Ile Met Gly Asn Glu 625 630 635 640 Lys Cys Ser Gln His His Arg Gly Lys Val Thr Leu Asn Glu Ser Glu 645 650 655 Ile Cys Ala Gly Ala Glu Lys Ile Gly Ser Gly Pro Cys Glu Gly Asp 660 665 670 Tyr Gly Gly Pro Leu Val Cys Glu Gln His Lys Met Arg Met Val Leu 675 680 685 Gly Val Ile Val Pro Gly Arg Gly Cys Ala Ile Pro Asn Arg Pro Gly 690 695 700 Ile Phe Val Arg Val Ala Tyr Tyr Ala Lys Trp Ile His Lys Ile Ile 705 710 715 720 Leu Thr Tyr Lys Val Pro Gln Ser 725 2723PRTArtificial Sequenceamino acid sequence of dHGF 2Met Trp Val Thr Lys Leu Leu Pro Ala Leu Leu Leu Gln His Val Leu 1 5 10 15 Leu His Leu Leu Leu Leu Pro Ile Ala Ile Pro Tyr Ala Glu Gly Gln 20 25 30 Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys Thr 35 40 45 Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys Lys Val 50 55 60 Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly Leu 65 70 75 80 Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys Gln Cys 85 90 95 Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu Phe 100 105 110 Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn Cys 115 120 125 Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val Ser Ile Thr Lys 130 135 140 Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu His 145 150 155 160 Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn Tyr Cys Arg Asn Pro Arg 165 170 175 Gly Glu Glu Gly Gly Pro Trp Cys Phe Thr Ser Asn Pro Glu Val Arg 180 185 190 Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser Glu Val Glu Cys Met Thr 195 200 205 Cys Asn Gly Glu Ser Tyr Arg Gly Leu Met Asp His Thr Glu Ser Gly 210 215 220 Lys Ile Cys Gln Arg Trp Asp His Gln Thr Pro His Arg His Lys Phe 225 230 235 240 Leu Pro Glu Arg Tyr Pro Asp Lys Gly Phe Asp Asp Asn Tyr Cys Arg 245 250 255 Asn Pro Asp Gly Gln Pro Arg Pro Trp Cys Tyr Thr Leu Asp Pro His 260 265 270 Thr Arg Trp Glu Tyr Cys Ala Ile Lys Thr Cys Ala Asp Asn Thr Met 275 280 285 Asn Asp Thr Asp Val Pro Leu Glu Thr Thr Glu Cys Ile Gln Gly Gln 290 295 300 Gly Glu Gly Tyr Arg Gly Thr Val Asn Thr Ile Trp Asn Gly Ile Pro 305 310 315 320 Cys Gln Arg Trp Asp Ser Gln Tyr Pro His Glu His Asp Met Thr Pro 325 330 335 Glu Asn Phe Lys Cys Lys Asp Leu Arg Glu Asn Tyr Cys Arg Asn Pro 340 345 350 Asp Gly Ser Glu Ser Pro Trp Cys Phe Thr Thr Asp Pro Asn Ile Arg 355 360 365 Val Gly Tyr Cys Ser Gln Ile Pro Asn Cys Asp Met Ser His Gly Gln 370 375 380 Asp Cys Tyr Arg Gly Asn Gly Lys Asn Tyr Met Gly Asn Leu Ser Gln 385 390 395 400 Thr Arg Ser Gly Leu Thr Cys Ser Met Trp Asp Lys Asn Met Glu Asp 405 410 415 Leu His Arg His Ile Phe Trp Glu Pro Asp Ala Ser Lys Leu Asn Glu 420 425 430 Asn Tyr Cys Arg Asn Pro Asp Asp Asp Ala His Gly Pro Trp Cys Tyr 435 440 445 Thr Gly Asn Pro Leu Ile Pro Trp Asp Tyr Cys Pro Ile Ser Arg Cys 450 455 460 Glu Gly Asp Thr Thr Pro Thr Ile Val Asn Leu Asp His Pro Val Ile 465 470 475 480 Ser Cys Ala Lys Thr Lys Gln Leu Arg Val Val Asn Gly Ile Pro Thr 485 490 495 Arg Thr Asn Ile Gly Trp Met Val Ser Leu Arg Tyr Arg Asn Lys His 500 505 510 Ile Cys Gly Gly Ser Leu Ile Lys Glu Ser Trp Val Leu Thr Ala Arg 515 520 525 Gln Cys Phe Pro Ser Arg Asp Leu Lys Asp Tyr Glu Ala Trp Leu Gly 530 535 540 Ile His Asp Val His Gly Arg Gly Asp Glu Lys Cys Lys Gln Val Leu 545 550 555 560 Asn Val Ser Gln Leu Val Tyr Gly Pro Glu Gly Ser Asp Leu Val Leu 565 570 575 Met Lys Leu Ala Arg Pro Ala Val Leu Asp Asp Phe Val Ser Thr Ile 580 585 590 Asp Leu Pro Asn Tyr Gly Cys Thr Ile Pro Glu Lys Thr Ser Cys Ser 595 600 605 Val Tyr Gly Trp Gly Tyr Thr Gly Leu Ile Asn Tyr Asp Gly Leu Leu 610 615 620 Arg Val Ala His Leu Tyr Ile Met Gly Asn Glu Lys Cys Ser Gln His 625 630 635 640 His Arg Gly Lys Val Thr Leu Asn Glu Ser Glu Ile Cys Ala Gly Ala 645 650 655 Glu Lys Ile Gly Ser Gly Pro Cys Glu Gly Asp Tyr Gly Gly Pro Leu 660 665 670 Val Cys Glu Gln His Lys Met Arg Met Val Leu Gly Val Ile Val Pro 675 680 685 Gly Arg Gly Cys Ala Ile Pro Asn Arg Pro Gly Ile Phe Val Arg Val 690 695 700 Ala Tyr Tyr Ala Lys Trp Ile His Lys Ile Ile Leu Thr Tyr Lys Val 705 710 715 720 Pro Gln Ser 3207PRTArtificial Sequenceamino acid sequence of NK1 3Met Trp Val Thr Lys Leu Leu Pro Ala Leu Leu Leu Gln His Val Leu 1 5 10 15 Leu His Leu Leu Leu Leu Pro Ile Ala Ile Pro Tyr Ala Glu Gly Gln 20 25 30 Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys Thr 35 40 45 Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys Lys Val 50 55 60 Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly Leu 65 70 75 80 Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys Gln Cys 85 90 95 Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu Phe 100 105 110 Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn Cys 115 120 125 Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val Ser Ile Thr Lys 130 135 140 Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu His 145 150 155 160 Ser Phe Leu Pro Ser Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn Tyr 165 170 175 Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp Cys Phe Thr Ser 180 185 190 Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser 195 200 205 4290PRTArtificial Sequenceamino acid sequence of NK2 4Met Trp Val Thr Lys Leu Leu Pro Ala Leu Leu Leu Gln His Val Leu 1 5 10 15 Leu His Leu Leu Leu Leu Pro Ile Ala Ile Pro Tyr Ala Glu Gly Gln 20 25 30 Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys Thr 35 40 45 Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys Lys Val 50 55 60 Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly Leu 65 70 75 80 Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys Gln Cys 85 90 95 Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu Phe 100 105 110 Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn Cys 115 120 125 Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val Ser Ile Thr Lys 130 135 140 Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu His 145 150 155 160 Ser Phe Leu Pro Ser Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn Tyr 165 170 175 Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp Cys Phe Thr Ser 180 185 190 Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser Glu 195 200 205 Val Glu Cys Met Thr Cys Asn Gly Glu Ser Tyr Arg Gly Leu Met Asp 210 215 220 His Thr Glu Ser Gly Lys Ile Cys Gln Arg Trp Asp His Gln Thr Pro 225 230 235 240 His Arg His Lys Phe Leu Pro Glu Arg Tyr Pro Asp Lys Gly Phe Asp 245 250 255 Asp Asn Tyr Cys Arg Asn Pro Asp Gly Gln Pro Arg Pro Trp Cys Tyr 260 265 270 Thr Leu Asp Pro His Thr Arg Trp Glu Tyr Cys Ala Ile Lys Thr Cys 275 280 285 Glu Thr 290 5470PRTArtificial Sequenceamino acid sequence of NK4 5Met Trp Val Thr Lys Leu Leu Pro Ala Leu Leu Leu Gln His Val Leu 1 5 10 15 Leu His Leu Leu Leu Leu Pro Ile Ala Ile Pro Tyr Ala Glu Gly Gln 20 25 30 Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys Thr 35 40 45 Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys Lys Val 50 55 60 Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly Leu 65 70 75 80 Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys Gln Cys 85 90 95 Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu Phe 100 105 110 Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn Cys 115 120 125 Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val Ser Ile Thr Lys 130 135 140 Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu His 145 150 155 160 Ser Phe Leu Pro Ser Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn Tyr 165 170 175 Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp Cys Phe Thr Ser 180 185 190 Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser Glu 195 200 205 Val Glu Cys Met Thr Cys Asn Gly Glu Ser Tyr Arg Gly Leu Met Asp 210 215 220 His Thr Glu Ser Gly Lys Ile Cys Gln Arg Trp Asp His Gln Thr Pro 225 230 235 240 His Arg His Lys Phe Leu Pro Glu Arg Tyr Pro Asp Lys Gly Phe Asp 245 250 255 Asp Asn Tyr Cys Arg Asn Pro Asp Gly Gln Pro Arg Pro Trp Cys Tyr 260 265 270 Thr Leu Asp Pro His Thr Arg Trp Glu Tyr Cys Ala Ile Lys Thr Cys 275 280 285 Ala Asp Asn Thr Met Asn Asp Thr Asp Val Pro Leu Glu Thr Thr Glu 290 295 300 Cys Ile Gln Gly Gln Gly Glu Gly Tyr Arg Gly Thr Val Asn Thr Ile 305 310 315 320 Trp Asn Gly Ile Pro Cys Gln Arg Trp Asp

Ser Gln Tyr Pro His Glu 325 330 335 His Asp Met Thr Pro Glu Asn Phe Lys Cys Lys Asp Leu Arg Glu Asn 340 345 350 Tyr Cys Arg Asn Pro Asp Gly Ser Glu Ser Pro Trp Cys Phe Thr Thr 355 360 365 Asp Pro Asn Ile Arg Val Gly Tyr Cys Ser Gln Ile Pro Asn Cys Asp 370 375 380 Met Ser His Gly Gln Asp Cys Tyr Arg Gly Asn Gly Lys Asn Tyr Met 385 390 395 400 Gly Asn Leu Ser Gln Thr Arg Ser Gly Leu Thr Cys Ser Met Trp Asp 405 410 415 Lys Asn Met Glu Asp Leu His Arg His Ile Phe Trp Glu Pro Asp Ala 420 425 430 Ser Lys Leu Asn Glu Asn Tyr Cys Arg Asn Pro Asp Asp Asp Ala His 435 440 445 Gly Pro Trp Cys Tyr Thr Gly Asn Pro Leu Ile Pro Trp Asp Tyr Cys 450 455 460 Pro Ile Ser Arg Cys Glu 465 470 62187DNAArtificial Sequencenucleotide sequence of cHGF 6atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180accaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggaacagta 420tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480agctttttgc cttcgagcta tcggggtaaa gacctacagg aaaactactg tcgaaatcct 540cgaggggaag aagggggacc ctggtgtttc acaagcaatc cagaggtacg ctacgaagtc 600tgtgacattc ctcagtgttc agaagttgaa tgcatgacct gcaatgggga gagttatcga 660ggtctcatgg atcatacaga atcaggcaag atttgtcagc gctgggatca tcagacacca 720caccggcaca aattcttgcc tgaaagatat cccgacaagg gctttgatga taattattgc 780cgcaatcccg atggccagcc gaggccatgg tgctatactc ttgaccctca cacccgctgg 840gagtactgtg caattaaaac atgcgctgac aatactatga atgacactga tgttcctttg 900gaaacaactg aatgcatcca aggtcaagga gaaggctaca ggggcactgt caataccatt 960tggaatggaa ttccatgtca gcgttgggat tctcagtatc ctcacgagca tgacatgact 1020cctgaaaatt tcaagtgcaa ggacctacga gaaaattact gccgaaatcc agatgggtct 1080gaatcaccct ggtgttttac cactgatcca aacatccgag ttggctactg ctcccaaatt 1140ccaaactgtg atatgtcaca tggacaagat tgttatcgtg ggaatggcaa aaattatatg 1200ggcaacttat cccaaacaag atctggacta acatgttcaa tgtgggacaa gaacatggaa 1260gacttacatc gtcatatctt ctgggaacca gatgcaagta agctgaatga gaattactgc 1320cgaaatccag atgatgatgc tcatggaccc tggtgctaca cgggaaatcc actcattcct 1380tgggattatt gccctatttc tcgttgtgaa ggtgatacca cacctacaat agtcaattta 1440gaccatcccg taatatcttg tgccaaaacg aaacaattgc gagttgtaaa tgggattcca 1500acacgaacaa acataggatg gatggttagt ttgagataca gaaataaaca tatctgcgga 1560ggatcattga taaaggagag ttgggttctt actgcacgac agtgtttccc ttctcgagac 1620ttgaaagatt atgaagcttg gcttggaatt catgatgtcc acggaagagg agatgagaaa 1680tgcaaacagg ttctcaatgt ttcccagctg gtatatggcc ctgaaggatc agatctggtt 1740ttaatgaagc ttgccaggcc tgctgtcctg gatgattttg ttagtacgat tgatttacct 1800aattatggat gcacaattcc tgaaaagacc agttgcagtg tttatggctg gggctacact 1860ggattgatca actatgatgg cctattacga gtggcacatc tctatataat gggaaatgag 1920aaatgcagcc agcatcatcg agggaaggtg actctgaatg agtctgaaat atgtgctggg 1980gctgaaaaga ttggatcagg accatgtgag ggggattatg gtggcccact tgtttgtgag 2040caacataaaa tgagaatggt tcttggtgtc attgttcctg gtcgtggatg tgccattcca 2100aatcgtcctg gtatttttgt ccgagtagca tattatgcaa aatggataca caaaattatt 2160ttaacatata aggtaccaca gtcatag 218777113DNAArtificial Sequencenucleotide sequence of hybrid HGF 7atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180accaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggaacagta 420tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc 540tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660tgttaataaa atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg 720tatttgtgaa ataataacgt aaacttcgtt taaaaggatt cttcttcctg tctttgagaa 780agtacggcac tgtgcagggg gagaggttga ttgtgaaaaa tcagaggtag atgagaatct 840tactgagggc tgagggttct ttaaccttgg tggatctcaa cattggttgc acattaaaat 900cacctgctgc aagcccttga cgaatcttac ttagaagatg acaacacaga acaattaaat 960cagaatctct ggggagaata gggcaccagt attttttgag ctcccaccat gattccaaag 1020tgcagccaaa tttgagaacc actgctaaaa gctcaagctt cagattgacc agcttttcca 1080tctcacctat cgcctaaaga ccaaattgga taaatgtgtt cattacgaca gatgggtact 1140atttaaagat gagtaaacac aatatactta ggctcgtcag actgagagtt ttaatcatca 1200ctgaggaaaa acatagatat ctaatactga ctggagtatt agtcaaggct tatttcacac 1260acaattttat cagaaaccaa agtagtttaa aacagctctc cccttattag taatgcattg 1320gagggtttac tttaccatgt accttgctga gcactgtacc ttgttaatct catttacttg 1380taatgagaac cacacagcgg gtagttttat tggttctatt ttacctacat gacaaaactg 1440aagcataaaa acacttagta agttttcagt gtcatgcaca actaggaagt gacatggcca 1500gaatataagc ccagtcacca tcactctata acctgcgctt ttaacaactt cagggcatga 1560cacatttggc cggtcagtag aacccatgct gtgatttgtt tttgcagtgg tggtgatgac 1620tgccttgttg aatccacttt ttattctatt ccattttggg gacacaattc tgcaagatga 1680ttcttcatta ggaaacagag atgagttatt gaccaacaca gaaagaaaaa gagtttgttg 1740ctccacactg ggattaaacc tatgatcttg gcctaattaa cactagctag taagtgtcca 1800agctgatcat ctctacaaca tttcaataac agaaaacaac aattttcaaa attagttact 1860tacaattatg tagaaatgcc tctaaaacac agtattttcc ttatattaca aaaacaaaaa 1920ttataattgg ttttgtcctc ttttgagagt ttgcatggtg ttactccctg catagtgaag 1980aaaacatttt atttaagtag atggatctaa gtttttcatg aacaaaggaa tgacatttga 2040aatcaatcct accctagtcc aggagaatgc attagattaa cctagtagag gtcttatttc 2100accctgagtt ttctatgatc gtgattctct gctggaggag taattgtgaa atagatctct 2160ctgggaactg gcttcctagt ccaatcagct cttttaccaa tgaacacttc cttgtgatat 2220agatgtttat ggccgagagg atccagtata ttaataaaat ccctttttgt attcaatgag 2280ggaaacacat aattttcatc aattagcagc ttattggaat atctgcatga tggtttaaca 2340cttttaagtg ttgactaaag attaatttta cagaaaatag aaaaagaaat atgtttctgt 2400ctggaggaat gatttattgt tgacccctaa attgaaatat tttactagtg gcttaatgga 2460aagatgatga aagatgatga aattaatgta gaagcttaac tagaaaatca ggtgacctga 2520tatctacatc tgtatccttc attggccacc cagcattcat taatgaatca gatgatggaa 2580tagatcaagt ttcctaggaa cacagtgaat attaaaagaa aacaaaggga gcctagcacc 2640tagaagacct agtttatatt tcaaagtata tttggatgta acccaatttt aaacatttcc 2700tcacttgtct ctcttaaagc cttgccaaca gcaaggacag agaaccaaaa atagtgtata 2760tatgaataaa tgcttattac agaatctgct gactggcaca tgctttgtgt gtaatgggtt 2820ctcataaaca cttgttgaat gaacacacat aagtgaaaga gcatggctag gcttcatccc 2880ttggtcaaat atggggtgct aaagaaaagc aggggaaata cattgggaca ctaacaaaaa 2940aaaacagtta atttaggtaa aagataaaat acaccacaga atgaagaaaa gagatgaccc 3000agactgctct ttaaccttca tgtcctagag aggtttttga tatgaattgc attcagaatt 3060gtggaaagga gcccatcttt tctcttcatt ttgattttat taactccaat gggggaattt 3120tattcgtgtt ttggccatat ctacttttga tttctacatt attctctctt cctttctacc 3180tgtatttgtc ctaataaatt gttgacttat taattcacta cttcctcaca gctttttttt 3240ggctttacaa atccactgga aaggtatatg ggtgtatcac tttgtgtatt tcggtgtgca 3300tgtgtagagg ggacaaaaat cctctctcaa actataaata ttgagtattt gtgtattgaa 3360catttgctat aactactagg tttcttaaat aatcttaata tataaaatga tatagaaaaa 3420gggaaattat agttcgtatt attcatctaa gtgaagagat taaaacccag ggagtaaata 3480aattgtctaa ggactaaggt tgtatactat ttaggtgata gatatggggc aaccgtatgg 3540gttttatgat taacaaataa acttctcacc actctaccat atcaactttt ccataaaaga 3600gagctatagt attctttgct taaataaatt tgattagtgc atgacttctt gaaaacatat 3660aaagcaaaag tcacatttga ttctatcaga aaagtgagta agccatggcc caaacaaaag 3720atgcattaaa atattctgga atgatggagc taaaagtaag aaaaatgact ttttaaaaaa 3780gtttactgtt aggaattgtg aaattatgct gaattttagt tgcattataa tttttgtcag 3840tcatacggtc tgacaacctg tcttatttct atttccccat atgaggaatg ctagttaagt 3900atggatatta actattacta cttagatgca ttgaagttgc ataatatgga taatacttca 3960ctggttccct gaaaatgttt agttagtaat aagtctctta cactatttgt tttgtccaat 4020aatttatatt ttctgaagac ttaactctag aatacactca tgtcaaaatg aaagaatttc 4080attgcaaaat attgcttggt acatgacgca tacctgtatt tgttttgtgt cacaacatga 4140aaaatgatgg tttattagaa gtttcattgg gtaggaaaca catttgaatg gtatttacta 4200agatactaaa atccttggac ttcactctaa ttttagtgcc atttagaact caaggtctca 4260gtaaaagtag aaataaagcc tgttaacaaa acacaagctg aatattaaaa atgtaactgg 4320attttcaaag aaatgtttac tggtattacc tgtagatgta tattctttat tatgatcttt 4380tgtgtaaagt ctggcagaca aatgcaatat ctaattgttg agtccaatat cacaagcagt 4440acaaaagtat aaaaaagact tggccttttc taatgtgtta aaatacttta tgctggtaat 4500aacactaaga gtagggcact agaaatttta agtgaagata atgtgttgca gttactgcac 4560tcaatggctt actattataa accaaaactg ggatcactaa gctccagtca gtcaaaatga 4620tcaaaattat tgaagagaat aagcaattct gttctttatt aggacacagt agatacagac 4680tacaaagtgg agtgtgctta ataagaggta gcatttgtta agtgtcaatt actctattat 4740cccttggagc ttctcaaaat aaccatataa ggtgtaagat gttaaaggtt atggttacac 4800tcagtgcaca ggtaagctaa taggctgaga gaagctaaat tacttactgg ggtctcacag 4860taagaaagtg agctgaagtt tcagcccaga tttaactgga ttctgggctc tttattcatg 4920ttacttcatg aatctgtttc tcaattgtgc agaaaaaagg gggctattta taagaaaagc 4980aataaacaaa caagtaatga tctcaaataa gtaatgcaag aaatagtgag atttcaaaat 5040cagtggcagc gatttctcag ttctgtccta agtggccttg ctcaatcacc tgctatcttt 5100tagtggagct ttgaaattat gtttcagaca acttcgattc agttctagaa tgtttgactc 5160agcaaattca caggctcatc tttctaactt gatggtgaat atggaaattc agctaaatgg 5220atgttaataa aattcaaacg ttttaaggac agatgaaaat gacagaattt taaggtaaaa 5280tatatgaagg aatataagat aaaggatttt tctaccttca gcaaaaacat acccactaat 5340tagtaaaatt aataggcaaa aaaaagttgc atgctcttat actgtaatga ttatcatttt 5400aaaactagct ttttgccttc gagctatcgg ggtaaagacc tacaggaaaa ctactgtcga 5460aatcctcgag gggaagaagg gggaccctgg tgtttcacaa gcaatccaga ggtacgctac 5520gaagtctgtg acattcctca gtgttcagaa gttgaatgca tgacctgcaa tggggagagt 5580tatcgaggtc tcatggatca tacagaatca ggcaagattt gtcagcgctg ggatcatcag 5640acaccacacc ggcacaaatt cttgcctgaa agatatcccg acaagggctt tgatgataat 5700tattgccgca atcccgatgg ccagccgagg ccatggtgct atactcttga ccctcacacc 5760cgctgggagt actgtgcaat taaaacatgc gctgacaata ctatgaatga cactgatgtt 5820cctttggaaa caactgaatg catccaaggt caaggagaag gctacagggg cactgtcaat 5880accatttgga atggaattcc atgtcagcgt tgggattctc agtatcctca cgagcatgac 5940atgactcctg aaaatttcaa gtgcaaggac ctacgagaaa attactgccg aaatccagat 6000gggtctgaat caccctggtg ttttaccact gatccaaaca tccgagttgg ctactgctcc 6060caaattccaa actgtgatat gtcacatgga caagattgtt atcgtgggaa tggcaaaaat 6120tatatgggca acttatccca aacaagatct ggactaacat gttcaatgtg ggacaagaac 6180atggaagact tacatcgtca tatcttctgg gaaccagatg caagtaagct gaatgagaat 6240tactgccgaa atccagatga tgatgctcat ggaccctggt gctacacggg aaatccactc 6300attccttggg attattgccc tatttctcgt tgtgaaggtg ataccacacc tacaatagtc 6360aatttagacc atcccgtaat atcttgtgcc aaaacgaaac aattgcgagt tgtaaatggg 6420attccaacac gaacaaacat aggatggatg gttagtttga gatacagaaa taaacatatc 6480tgcggaggat cattgataaa ggagagttgg gttcttactg cacgacagtg tttcccttct 6540cgagacttga aagattatga agcttggctt ggaattcatg atgtccacgg aagaggagat 6600gagaaatgca aacaggttct caatgtttcc cagctggtat atggccctga aggatcagat 6660ctggttttaa tgaagcttgc caggcctgct gtcctggatg attttgttag tacgattgat 6720ttacctaatt atggatgcac aattcctgaa aagaccagtt gcagtgttta tggctggggc 6780tacactggat tgatcaacta tgatggccta ttacgagtgg cacatctcta tataatggga 6840aatgagaaat gcagccagca tcatcgaggg aaggtgactc tgaatgagtc tgaaatatgt 6900gctggggctg aaaagattgg atcaggacca tgtgaggggg attatggtgg cccacttgtt 6960tgtgagcaac ataaaatgag aatggttctt ggtgtcattg ttcctggtcg tggatgtgcc 7020attccaaatc gtcctggtat ttttgtccga gtagcatatt atgcaaaatg gatacacaaa 7080attattttaa catataaggt accacagtca tag 711386190DNAArtificial Sequencenucleotide sequence of HGF-X2 8atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180accaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggaacagta 420tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc 540tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660tgttaataaa atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg 720tatttgtgaa ataataacgt aaacttcgtt taaaaggatt cttcttcctg tctttgagaa 780agtacggcac tgtgcagggg gagaggttga ttgtgaaaaa tcagaggtag atgagaatct 840tactgagggc tgagggttct ttaaccttgg tggatctcaa cattggttgc acattaaaat 900cacctgctgc aagcccttga cgaatcttac ttagaagatg acaacacaga acaattaaat 960cagaatctct ggggagaata gggcaccagt attttttgag ctcccaccat gattccaaag 1020tgcagccaaa tttgagaacc actgctaaaa gctcaagctt cagattgacc agcttttcca 1080tctcacctat cgcctaaaga ccaaattgga taaatgtgtt cattacgaca gatgggtact 1140atttaaagat gagtaaacac aatatactta ggctcgtcag actgagagtt ttaatcatca 1200ctgaggaaaa acatagatat ctaatactga ctggagtatt agtcaaggct tatttcacac 1260acaattttat cagaaaccaa agtagtttaa aacagctctc cccttattag taatgcattg 1320gagggtttac tttaccatgt accttgctga gcactgtacc ttgttaatct catttacttg 1380taatgagaac cacacagcgg gtagttttat tggttctatt ttacctacat gacaaaactg 1440aagcataaaa acacttagta agttttcagt gtcatgcaca actaggaagt gacatggcca 1500gaatataagc ccagtcacca tcactctata acctgcgctt ttaacaactt cagggcatga 1560cacatttggc cggtcagtag aacccatgct gtgatttgtt tttgcagtgg tggtgatgac 1620tgccttgttg aatccacttt ttattctatt ccattttggg gacacaattc tgcaagatga 1680ttcttcatta ggaaacagag atgagttatt gaccaacaca gaaagaaaaa gagtttgttg 1740ctccacactg ggattaaacc tatgatcttg gcctaattaa cactagctag taagtgtcca 1800agctgatcat ctctacaaca tttcaataac agaaaacaac aattttcaaa attagttact 1860tacaattatg tagaaatgcc tctaaaacac agtattttcc ttatattaca aaaacaaaaa 1920ttataattgg ttttgtcctc ttttgagagt ttgcatggtg ttactccctg catagtgaag 1980aaaacatttt atttaagtag atggatctaa gtttttcatg aacaaaggaa tgacatttga 2040aatcaatcct accctagtcc aggagaatgc attagattaa cctagtagag gtcttatttc 2100accctgagtt ttctatgatc gtgattctct gctggaggag taattgtgaa atagatctct 2160ctgggaactg gcttcctagt ccaatcagct cttttaccaa tgaacacttc cttgtgatat 2220agatgtttat ggccgagagg atcccttcct ttctacctgt atttgtccta ataaattgtt 2280gacttattaa ttcactactt cctcacagct tttttttggc tttacaaatc cactggaaag 2340gtatatgggt gtatcacttt gtgtatttcg gtgtgcatgt gtagagggga caaaaatcct 2400ctctcaaact ataaatattg agtatttgtg tattgaacat ttgctataac tactaggttt 2460cttaaataat cttaatatat aaaatgatat agaaaaaggg aaattatagt tcgtattatt 2520catctaagtg aagagattaa aacccaggga gtaaataaat tgtctaagga ctaaggttgt 2580atactattta ggtgatagat atggggcaac cgtatgggtt ttatgattaa caaataaact 2640tctcaccact ctaccatatc aacttttcca taaaagagag ctatagtatt ctttgcttaa 2700ataaatttga ttagtgcatg acttcttgaa aacatataaa gcaaaagtca catttgattc 2760tatcagaaaa gtgagtaagc catggcccaa acaaaagatg cattaaaata ttctggaatg 2820atggagctaa aagtaagaaa aatgactttt taaaaaagtt tactgttagg aattgtgaaa 2880ttatgctgaa ttttagttgc attataattt ttgtcagtca tacggtctga caacctgtct 2940tatttctatt tccccatatg aggaatgcta gttaagtatg gatattaact attactactt 3000agatgcattg aagttgcata atatggataa tacttcactg gttccctgaa aatgtttagt 3060tagtaataag tctcttacac tatttgtttt gtccaataat ttatattttc tgaagactta 3120actctagaat acactcatgt caaaatgaaa gaatttcatt gcaaaatatt gcttggtaca 3180tgacgcatac ctgtatttgt tttgtgtcac aacatgaaaa atgatggttt attagaagtt 3240tcattgggta ggaaacacat ttgaatggta tttactaaga tactaaaatc cttggacttc 3300actctaattt tagtgccatt tagaactcaa ggtctcagta aaagtagaaa taaagcctgt 3360taacaaaaca caagctgaat attaaaaatg taactggatt ttcaaagaaa tgtttactgg 3420tattacctgt agatgtatat tctttattat gatcttttgt gtaaagtctg gcagacaaat 3480gcaatatcta attgttgagt ccaatatcac aagcagtaca aaagtataaa aaagacttgg 3540ccttttctaa tgtgttaaaa tactttatgc tggtaataac actaagagta gggcactaga 3600aattttaagt gaagataatg tgttgcagtt actgcactca atggcttact attataaacc 3660aaaactggga tcactaagct ccagtcagtc aaaatgatca aaattattga agagaataag 3720caattctgtt ctttattagg acacagtaga tacagactac aaagtggagt gtgcttaata 3780agaggtagca tttgttaagt gtcaattact ctattatccc ttggagcttc tcaaaataac 3840catataaggt gtaagatgtt aaaggttatg gttacactca gtgcacaggt aagctaatag 3900gctgagagaa gctaaattac ttactggggt ctcacagtaa gaaagtgagc tgaagtttca 3960gcccagattt aactggattc tgggctcttt attcatgtta cttcatgaat ctgtttctca 4020attgtgcaga aaaaaggggg ctatttataa gaaaagcaat aaacaaacaa gtaatgatct 4080caaataagta atgcaagaaa tagtgagatt tcaaaatcag tggcagcgat ttctcagttc 4140tgtcctaagt ggccttgctc aatcacctgc tatcttttag tggagctttg aaattatgtt 4200tcagacaact tcgattcagt tctagaatgt ttgactcagc aaattcacag gctcatcttt 4260ctaacttgat ggtgaatatg gaaattcagc taaatggatg ttaataaaat tcaaacgttt 4320taaggacaga tgaaaatgac agaattttaa ggtaaaatat atgaaggaat ataagataaa 4380ggatttttct accttcagca aaaacatacc cactaattag taaaattaat aggcaaaaaa 4440aagttgcatg ctcttatact gtaatgatta tcattttaaa actagctttt tgccttcgag 4500ctatcggggt aaagacctac aggaaaacta ctgtcgaaat cctcgagggg aagaaggggg 4560accctggtgt ttcacaagca atccagaggt

acgctacgaa gtctgtgaca ttcctcagtg 4620ttcagaagtt gaatgcatga cctgcaatgg ggagagttat cgaggtctca tggatcatac 4680agaatcaggc aagatttgtc agcgctggga tcatcagaca ccacaccggc acaaattctt 4740gcctgaaaga tatcccgaca agggctttga tgataattat tgccgcaatc ccgatggcca 4800gccgaggcca tggtgctata ctcttgaccc tcacacccgc tgggagtact gtgcaattaa 4860aacatgcgct gacaatacta tgaatgacac tgatgttcct ttggaaacaa ctgaatgcat 4920ccaaggtcaa ggagaaggct acaggggcac tgtcaatacc atttggaatg gaattccatg 4980tcagcgttgg gattctcagt atcctcacga gcatgacatg actcctgaaa atttcaagtg 5040caaggaccta cgagaaaatt actgccgaaa tccagatggg tctgaatcac cctggtgttt 5100taccactgat ccaaacatcc gagttggcta ctgctcccaa attccaaact gtgatatgtc 5160acatggacaa gattgttatc gtgggaatgg caaaaattat atgggcaact tatcccaaac 5220aagatctgga ctaacatgtt caatgtggga caagaacatg gaagacttac atcgtcatat 5280cttctgggaa ccagatgcaa gtaagctgaa tgagaattac tgccgaaatc cagatgatga 5340tgctcatgga ccctggtgct acacgggaaa tccactcatt ccttgggatt attgccctat 5400ttctcgttgt gaaggtgata ccacacctac aatagtcaat ttagaccatc ccgtaatatc 5460ttgtgccaaa acgaaacaat tgcgagttgt aaatgggatt ccaacacgaa caaacatagg 5520atggatggtt agtttgagat acagaaataa acatatctgc ggaggatcat tgataaagga 5580gagttgggtt cttactgcac gacagtgttt cccttctcga gacttgaaag attatgaagc 5640ttggcttgga attcatgatg tccacggaag aggagatgag aaatgcaaac aggttctcaa 5700tgtttcccag ctggtatatg gccctgaagg atcagatctg gttttaatga agcttgccag 5760gcctgctgtc ctggatgatt ttgttagtac gattgattta cctaattatg gatgcacaat 5820tcctgaaaag accagttgca gtgtttatgg ctggggctac actggattga tcaactatga 5880tggcctatta cgagtggcac atctctatat aatgggaaat gagaaatgca gccagcatca 5940tcgagggaag gtgactctga atgagtctga aatatgtgct ggggctgaaa agattggatc 6000aggaccatgt gagggggatt atggtggccc acttgtttgt gagcaacata aaatgagaat 6060ggttcttggt gtcattgttc ctggtcgtgg atgtgccatt ccaaatcgtc ctggtatttt 6120tgtccgagta gcatattatg caaaatggat acacaaaatt attttaacat ataaggtacc 6180acagtcatag 619095190DNAArtificial Sequencenucleotide sequence of HGF-X3 9atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180accaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggaacagta 420tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc 540tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660tgttaataaa atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg 720tatttgtgaa ataataacgt aaacttcgtt taaaaggatt cttcttcctg tctttgagaa 780agtacggcac tgtgcagggg gagaggttga ttgtgaaaaa tcagaggtag atgagaatct 840tactgagggc tgagggttct ttaaccttgg tggatctcaa cattggttgc acattaaaat 900cacctgctgc aagcccttga cgaatcttac ttagaagatg acaacacaga acaattaaat 960cagaatctct ggggagaata gggcaccagt attttttgag ctcccaccat gattccaaag 1020tgcagccaaa tttgagaacc actgctaaaa gctcaagctt cagattgacc agcttttcca 1080tctcacctat cgcctaaaga ccaaattgga taaatgtgtt cattacgaca gatgggtact 1140atttaaagat gagtaaacac aatatactta ggctcgtcag actgagagtt ttaatcatca 1200ctgaggaaaa acatagatat ctaatactga ctggagtatt agtcaaggct tatttcacac 1260acaattttat cagaaaccaa agtagtttaa aacagctctc cccttattag taatgcattg 1320gagggtttac tttaccatgt accttgctga gcactgtacc ttgttaatct catttacttg 1380taatgagaac cacacagcgg gtagttttat tggttctatt ttacctacat gacaaaactg 1440aagcataaaa acacttagta agttttcagt gtcatgcaca actaggaagt gacatggcca 1500gaatataagc ccagtcacca tcactctata acctgcgctt ttaacaactt cagggcatga 1560cacatttggc cggtcagtag aacccatgct gtgatttgtt tttgcagtgg tggtgatgac 1620tgccttgttg aatccacttt ttattctatt ccattttggg gacacaattc tgcaagatga 1680ttcttcatta ggaaacagag atgagttatt gaccaacaca gaaagaaaaa gagtttgttg 1740ctccacactg ggattaaacc tatgatcttg gcctaattaa cactagctag taagtgtcca 1800agctgatcat ctctacaaca tttcaataac agaaaacaac aattttcaaa attagttact 1860tacaattatg tagaaatgcc tctaaaacac agtattttcc ttatattaca aaaacaaaaa 1920ttataattgg ttttgtcctc ttttgagagt ttgcatggtg ttactccctg catagtgaag 1980aaaacatttt atttaagtag atggatctaa gtttttcatg aacaaaggaa tgacatttga 2040aatcaatcct accctagtcc aggagaatgc attagattaa cctagtagag gtcttatttc 2100accctgagtt ttctatgatc gtgattctct gctggaggag taattgtgaa atagatctct 2160ctgggaactg gcttcctagt ccaatcagct cttttaccaa tgaacacttc cttgtgatat 2220agatgtttat ggccgagagg atcctgggta ggaaacacat ttgaatggta tttactaaga 2280tactaaaatc cttggacttc actctaattt tagtgccatt tagaactcaa ggtctcagta 2340aaagtagaaa taaagcctgt taacaaaaca caagctgaat attaaaaatg taactggatt 2400ttcaaagaaa tgtttactgg tattacctgt agatgtatat tctttattat gatcttttgt 2460gtaaagtctg gcagacaaat gcaatatcta attgttgagt ccaatatcac aagcagtaca 2520aaagtataaa aaagacttgg ccttttctaa tgtgttaaaa tactttatgc tggtaataac 2580actaagagta gggcactaga aattttaagt gaagataatg tgttgcagtt actgcactca 2640atggcttact attataaacc aaaactggga tcactaagct ccagtcagtc aaaatgatca 2700aaattattga agagaataag caattctgtt ctttattagg acacagtaga tacagactac 2760aaagtggagt gtgcttaata agaggtagca tttgttaagt gtcaattact ctattatccc 2820ttggagcttc tcaaaataac catataaggt gtaagatgtt aaaggttatg gttacactca 2880gtgcacaggt aagctaatag gctgagagaa gctaaattac ttactggggt ctcacagtaa 2940gaaagtgagc tgaagtttca gcccagattt aactggattc tgggctcttt attcatgtta 3000cttcatgaat ctgtttctca attgtgcaga aaaaaggggg ctatttataa gaaaagcaat 3060aaacaaacaa gtaatgatct caaataagta atgcaagaaa tagtgagatt tcaaaatcag 3120tggcagcgat ttctcagttc tgtcctaagt ggccttgctc aatcacctgc tatcttttag 3180tggagctttg aaattatgtt tcagacaact tcgattcagt tctagaatgt ttgactcagc 3240aaattcacag gctcatcttt ctaacttgat ggtgaatatg gaaattcagc taaatggatg 3300ttaataaaat tcaaacgttt taaggacaga tgaaaatgac agaattttaa ggtaaaatat 3360atgaaggaat ataagataaa ggatttttct accttcagca aaaacatacc cactaattag 3420taaaattaat aggcaaaaaa aagttgcatg ctcttatact gtaatgatta tcattttaaa 3480actagctttt tgccttcgag ctatcggggt aaagacctac aggaaaacta ctgtcgaaat 3540cctcgagggg aagaaggggg accctggtgt ttcacaagca atccagaggt acgctacgaa 3600gtctgtgaca ttcctcagtg ttcagaagtt gaatgcatga cctgcaatgg ggagagttat 3660cgaggtctca tggatcatac agaatcaggc aagatttgtc agcgctggga tcatcagaca 3720ccacaccggc acaaattctt gcctgaaaga tatcccgaca agggctttga tgataattat 3780tgccgcaatc ccgatggcca gccgaggcca tggtgctata ctcttgaccc tcacacccgc 3840tgggagtact gtgcaattaa aacatgcgct gacaatacta tgaatgacac tgatgttcct 3900ttggaaacaa ctgaatgcat ccaaggtcaa ggagaaggct acaggggcac tgtcaatacc 3960atttggaatg gaattccatg tcagcgttgg gattctcagt atcctcacga gcatgacatg 4020actcctgaaa atttcaagtg caaggaccta cgagaaaatt actgccgaaa tccagatggg 4080tctgaatcac cctggtgttt taccactgat ccaaacatcc gagttggcta ctgctcccaa 4140attccaaact gtgatatgtc acatggacaa gattgttatc gtgggaatgg caaaaattat 4200atgggcaact tatcccaaac aagatctgga ctaacatgtt caatgtggga caagaacatg 4260gaagacttac atcgtcatat cttctgggaa ccagatgcaa gtaagctgaa tgagaattac 4320tgccgaaatc cagatgatga tgctcatgga ccctggtgct acacgggaaa tccactcatt 4380ccttgggatt attgccctat ttctcgttgt gaaggtgata ccacacctac aatagtcaat 4440ttagaccatc ccgtaatatc ttgtgccaaa acgaaacaat tgcgagttgt aaatgggatt 4500ccaacacgaa caaacatagg atggatggtt agtttgagat acagaaataa acatatctgc 4560ggaggatcat tgataaagga gagttgggtt cttactgcac gacagtgttt cccttctcga 4620gacttgaaag attatgaagc ttggcttgga attcatgatg tccacggaag aggagatgag 4680aaatgcaaac aggttctcaa tgtttcccag ctggtatatg gccctgaagg atcagatctg 4740gttttaatga agcttgccag gcctgctgtc ctggatgatt ttgttagtac gattgattta 4800cctaattatg gatgcacaat tcctgaaaag accagttgca gtgtttatgg ctggggctac 4860actggattga tcaactatga tggcctatta cgagtggcac atctctatat aatgggaaat 4920gagaaatgca gccagcatca tcgagggaag gtgactctga atgagtctga aatatgtgct 4980ggggctgaaa agattggatc aggaccatgt gagggggatt atggtggccc acttgtttgt 5040gagcaacata aaatgagaat ggttcttggt gtcattgttc ctggtcgtgg atgtgccatt 5100ccaaatcgtc ctggtatttt tgtccgagta gcatattatg caaaatggat acacaaaatt 5160attttaacat ataaggtacc acagtcatag 5190104241DNAArtificial Sequencenucleotide sequence of HGF-X4 10atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180accaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggaacagta 420tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc 540tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660tgttaataaa atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg 720tatttgtgaa ataataacgt aaacttcgtt taaaaggatt cttcttcctg tctttgagaa 780agtacggcac tgtgcagggg gagaggttga ttgtgaaaaa tcagaggtag atgagaatct 840tactgagggc tgagggttct ttaaccttgg tggatctcaa cattggttgc acattaaaat 900cacctgctgc aagcccttga cgaatcttac ttagaagatg acaacacaga acaattaaat 960cagaatctct ggggagaata gggcaccagt attttttgag ctcccaccat gattccaaag 1020tgcagccaaa tttgagaacc actgctaaaa gctcaagctt cagattgacc agcttttcca 1080tctcacctat cgcctaaaga ccaaattgga taaatgtgtt cattacgaca gatgggtact 1140atttaaagat gagtaaacac aatatactta ggctcgtcag actgagagtt ttaatcatca 1200ctgaggaaaa acatagatat ctaatactga ctggagtatt agtcaaggct tatttcacac 1260acaattttat cagaaaccaa agtagtttaa aacagctctc cccttattag taatgcattg 1320gagggtttac tttaccatgt accttgctga gcactgtacc ttgttaatct catttacttg 1380taatgagaac cacacagcgg gtagttttat tggttctatt ttacctacat gacaaaactg 1440aagcataaaa acacttagta agttttcagt gtcatgcaca actaggaagt gacatggcca 1500gaatataagc ccagtcacca tcactctata acctgcgctt ttaacaactt cagggcatga 1560cacatttggc cggtcagtag aacccatgct gtgatttgtt tttgcagtgg tggtgatgac 1620tgccttgttg aatccacttt ttattctatt ccattttggg gacacaattc tgcaagatga 1680ttcttcatta ggaaacagag atgagttatt gaccaacaca gaaagaaaaa gagtttgttg 1740ctccacactg ggattaaacc tatgatcttg gcctaattaa cactagctag taagtgtcca 1800agctgatcat ctctacaaca tttcaataac agaaaacaac aattttcaaa attagttact 1860tacaattatg tagaaatgcc tctaaaacac agtattttcc ttatattaca aaaacaaaaa 1920ttataattgg ttttgtcctc ttttgagagt ttgcatggtg ttactccctg catagtgaag 1980aaaacatttt atttaagtag atggatctaa gtttttcatg aacaaaggaa tgacatttga 2040aatcaatcct accctagtcc aggagaatgc attagattaa cctagtagag gtcttatttc 2100accctgagtt ttctatgatc gtgattctct gctggaggag taattgtgaa atagatctct 2160ctgggaactg gcttcctagt ccaatcagct cttttaccaa tgaacacttc cttgtgatat 2220agatgtttat ggccgagagg atccttatgt ttcagacaac ttcgattcag ttctagaatg 2280tttgactcag caaattcaca ggctcatctt tctaacttga tggtgaatat ggaaattcag 2340ctaaatggat gttaataaaa ttcaaacgtt ttaaggacag atgaaaatga cagaatttta 2400aggtaaaata tatgaaggaa tataagataa aggatttttc taccttcagc aaaaacatac 2460ccactaatta gtaaaattaa taggcaaaaa aaagttgcat gctcttatac tgtaatgatt 2520atcattttaa aactagcttt ttgccttcga gctatcgggg taaagaccta caggaaaact 2580actgtcgaaa tcctcgaggg gaagaagggg gaccctggtg tttcacaagc aatccagagg 2640tacgctacga agtctgtgac attcctcagt gttcagaagt tgaatgcatg acctgcaatg 2700gggagagtta tcgaggtctc atggatcata cagaatcagg caagatttgt cagcgctggg 2760atcatcagac accacaccgg cacaaattct tgcctgaaag atatcccgac aagggctttg 2820atgataatta ttgccgcaat cccgatggcc agccgaggcc atggtgctat actcttgacc 2880ctcacacccg ctgggagtac tgtgcaatta aaacatgcgc tgacaatact atgaatgaca 2940ctgatgttcc tttggaaaca actgaatgca tccaaggtca aggagaaggc tacaggggca 3000ctgtcaatac catttggaat ggaattccat gtcagcgttg ggattctcag tatcctcacg 3060agcatgacat gactcctgaa aatttcaagt gcaaggacct acgagaaaat tactgccgaa 3120atccagatgg gtctgaatca ccctggtgtt ttaccactga tccaaacatc cgagttggct 3180actgctccca aattccaaac tgtgatatgt cacatggaca agattgttat cgtgggaatg 3240gcaaaaatta tatgggcaac ttatcccaaa caagatctgg actaacatgt tcaatgtggg 3300acaagaacat ggaagactta catcgtcata tcttctggga accagatgca agtaagctga 3360atgagaatta ctgccgaaat ccagatgatg atgctcatgg accctggtgc tacacgggaa 3420atccactcat tccttgggat tattgcccta tttctcgttg tgaaggtgat accacaccta 3480caatagtcaa tttagaccat cccgtaatat cttgtgccaa aacgaaacaa ttgcgagttg 3540taaatgggat tccaacacga acaaacatag gatggatggt tagtttgaga tacagaaata 3600aacatatctg cggaggatca ttgataaagg agagttgggt tcttactgca cgacagtgtt 3660tcccttctcg agacttgaaa gattatgaag cttggcttgg aattcatgat gtccacggaa 3720gaggagatga gaaatgcaaa caggttctca atgtttccca gctggtatat ggccctgaag 3780gatcagatct ggttttaatg aagcttgcca ggcctgctgt cctggatgat tttgttagta 3840cgattgattt acctaattat ggatgcacaa ttcctgaaaa gaccagttgc agtgtttatg 3900gctggggcta cactggattg atcaactatg atggcctatt acgagtggca catctctata 3960taatgggaaa tgagaaatgc agccagcatc atcgagggaa ggtgactctg aatgagtctg 4020aaatatgtgc tggggctgaa aagattggat caggaccatg tgagggggat tatggtggcc 4080cacttgtttg tgagcaacat aaaatgagaa tggttcttgg tgtcattgtt cctggtcgtg 4140gatgtgccat tccaaatcgt cctggtattt ttgtccgagt agcatattat gcaaaatgga 4200tacacaaaat tattttaaca tataaggtac cacagtcata g 4241115602DNAArtificial Sequencenucleotide sequence of HGF-X5 11atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180accaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggaacagta 420tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc 540tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660tgttaataaa atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg 720tatttgtgga tccagtatat taataaaatc cctttttgta ttcaatgagg gaaacacata 780attttcatca attagcagct tattggaata tctgcatgat ggtttaacac ttttaagtgt 840tgactaaaga ttaattttac agaaaataga aaaagaaata tgtttctgtc tggaggaatg 900atttattgtt gacccctaaa ttgaaatatt ttactagtgg cttaatggaa agatgatgaa 960agatgatgaa attaatgtag aagcttaact agaaaatcag gtgacctgat atctacatct 1020gtatccttca ttggccaccc agcattcatt aatgaatcag atgatggaat agatcaagtt 1080tcctaggaac acagtgaata ttaaaagaaa acaaagggag cctagcacct agaagaccta 1140gtttatattt caaagtatat ttggatgtaa cccaatttta aacatttcct cacttgtctc 1200tcttaaagcc ttgccaacag caaggacaga gaaccaaaaa tagtgtatat atgaataaat 1260gcttattaca gaatctgctg actggcacat gctttgtgtg taatgggttc tcataaacac 1320ttgttgaatg aacacacata agtgaaagag catggctagg cttcatccct tggtcaaata 1380tggggtgcta aagaaaagca ggggaaatac attgggacac taacaaaaaa aaacagttaa 1440tttaggtaaa agataaaata caccacagaa tgaagaaaag agatgaccca gactgctctt 1500taaccttcat gtcctagaga ggtttttgat atgaattgca ttcagaattg tggaaaggag 1560cccatctttt ctcttcattt tgattttatt aactccaatg ggggaatttt attcgtgttt 1620tggccatatc tacttttgat ttctacatta ttctctcttc ctttctacct gtatttgtcc 1680taataaattg ttgacttatt aattcactac ttcctcacag cttttttttg gctttacaaa 1740tccactggaa aggtatatgg gtgtatcact ttgtgtattt cggtgtgcat gtgtagaggg 1800gacaaaaatc ctctctcaaa ctataaatat tgagtatttg tgtattgaac atttgctata 1860actactaggt ttcttaaata atcttaatat ataaaatgat atagaaaaag ggaaattata 1920gttcgtatta ttcatctaag tgaagagatt aaaacccagg gagtaaataa attgtctaag 1980gactaaggtt gtatactatt taggtgatag atatggggca accgtatggg ttttatgatt 2040aacaaataaa cttctcacca ctctaccata tcaacttttc cataaaagag agctatagta 2100ttctttgctt aaataaattt gattagtgca tgacttcttg aaaacatata aagcaaaagt 2160cacatttgat tctatcagaa aagtgagtaa gccatggccc aaacaaaaga tgcattaaaa 2220tattctggaa tgatggagct aaaagtaaga aaaatgactt tttaaaaaag tttactgtta 2280ggaattgtga aattatgctg aattttagtt gcattataat ttttgtcagt catacggtct 2340gacaacctgt cttatttcta tttccccata tgaggaatgc tagttaagta tggatattaa 2400ctattactac ttagatgcat tgaagttgca taatatggat aatacttcac tggttccctg 2460aaaatgttta gttagtaata agtctcttac actatttgtt ttgtccaata atttatattt 2520tctgaagact taactctaga atacactcat gtcaaaatga aagaatttca ttgcaaaata 2580ttgcttggta catgacgcat acctgtattt gttttgtgtc acaacatgaa aaatgatggt 2640ttattagaag tttcattggg taggaaacac atttgaatgg tatttactaa gatactaaaa 2700tccttggact tcactctaat tttagtgcca tttagaactc aaggtctcag taaaagtaga 2760aataaagcct gttaacaaaa cacaagctga atattaaaaa tgtaactgga ttttcaaaga 2820aatgtttact ggtattacct gtagatgtat attctttatt atgatctttt gtgtaaagtc 2880tggcagacaa atgcaatatc taattgttga gtccaatatc acaagcagta caaaagtata 2940aaaaagactt ggccttttct aatgtgttaa aatactttat gctggtaata acactaagag 3000tagggcacta gaaattttaa gtgaagataa tgtgttgcag ttactgcact caatggctta 3060ctattataaa ccaaaactgg gatcactaag ctccagtcag tcaaaatgat caaaattatt 3120gaagagaata agcaattctg ttctttatta ggacacagta gatacagact acaaagtgga 3180gtgtgcttaa taagaggtag catttgttaa gtgtcaatta ctctattatc ccttggagct 3240tctcaaaata accatataag gtgtaagatg ttaaaggtta tggttacact cagtgcacag 3300gtaagctaat aggctgagag aagctaaatt acttactggg gtctcacagt aagaaagtga 3360gctgaagttt cagcccagat ttaactggat tctgggctct ttattcatgt tacttcatga 3420atctgtttct caattgtgca gaaaaaaggg ggctatttat aagaaaagca ataaacaaac 3480aagtaatgat ctcaaataag taatgcaaga aatagtgaga tttcaaaatc agtggcagcg 3540atttctcagt tctgtcctaa gtggccttgc tcaatcacct gctatctttt agtggagctt 3600tgaaattatg tttcagacaa cttcgattca gttctagaat gtttgactca gcaaattcac 3660aggctcatct ttctaacttg atggtgaata tggaaattca gctaaatgga tgttaataaa 3720attcaaacgt tttaaggaca gatgaaaatg

acagaatttt aaggtaaaat atatgaagga 3780atataagata aaggattttt ctaccttcag caaaaacata cccactaatt agtaaaatta 3840ataggcaaaa aaaagttgca tgctcttata ctgtaatgat tatcatttta aaactagctt 3900tttgccttcg agctatcggg gtaaagacct acaggaaaac tactgtcgaa atcctcgagg 3960ggaagaaggg ggaccctggt gtttcacaag caatccagag gtacgctacg aagtctgtga 4020cattcctcag tgttcagaag ttgaatgcat gacctgcaat ggggagagtt atcgaggtct 4080catggatcat acagaatcag gcaagatttg tcagcgctgg gatcatcaga caccacaccg 4140gcacaaattc ttgcctgaaa gatatcccga caagggcttt gatgataatt attgccgcaa 4200tcccgatggc cagccgaggc catggtgcta tactcttgac cctcacaccc gctgggagta 4260ctgtgcaatt aaaacatgcg ctgacaatac tatgaatgac actgatgttc ctttggaaac 4320aactgaatgc atccaaggtc aaggagaagg ctacaggggc actgtcaata ccatttggaa 4380tggaattcca tgtcagcgtt gggattctca gtatcctcac gagcatgaca tgactcctga 4440aaatttcaag tgcaaggacc tacgagaaaa ttactgccga aatccagatg ggtctgaatc 4500accctggtgt tttaccactg atccaaacat ccgagttggc tactgctccc aaattccaaa 4560ctgtgatatg tcacatggac aagattgtta tcgtgggaat ggcaaaaatt atatgggcaa 4620cttatcccaa acaagatctg gactaacatg ttcaatgtgg gacaagaaca tggaagactt 4680acatcgtcat atcttctggg aaccagatgc aagtaagctg aatgagaatt actgccgaaa 4740tccagatgat gatgctcatg gaccctggtg ctacacggga aatccactca ttccttggga 4800ttattgccct atttctcgtt gtgaaggtga taccacacct acaatagtca atttagacca 4860tcccgtaata tcttgtgcca aaacgaaaca attgcgagtt gtaaatggga ttccaacacg 4920aacaaacata ggatggatgg ttagtttgag atacagaaat aaacatatct gcggaggatc 4980attgataaag gagagttggg ttcttactgc acgacagtgt ttcccttctc gagacttgaa 5040agattatgaa gcttggcttg gaattcatga tgtccacgga agaggagatg agaaatgcaa 5100acaggttctc aatgtttccc agctggtata tggccctgaa ggatcagatc tggttttaat 5160gaagcttgcc aggcctgctg tcctggatga ttttgttagt acgattgatt tacctaatta 5220tggatgcaca attcctgaaa agaccagttg cagtgtttat ggctggggct acactggatt 5280gatcaactat gatggcctat tacgagtggc acatctctat ataatgggaa atgagaaatg 5340cagccagcat catcgaggga aggtgactct gaatgagtct gaaatatgtg ctggggctga 5400aaagattgga tcaggaccat gtgaggggga ttatggtggc ccacttgttt gtgagcaaca 5460taaaatgaga atggttcttg gtgtcattgt tcctggtcgt ggatgtgcca ttccaaatcg 5520tcctggtatt tttgtccgag tagcatatta tgcaaaatgg atacacaaaa ttattttaac 5580atataaggta ccacagtcat ag 5602124679DNAArtificial Sequencenucleotide sequence of HGF-X6 12atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180accaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggaacagta 420tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc 540tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660tgttaataaa atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg 720tatttgtgga tcccttcctt tctacctgta tttgtcctaa taaattgttg acttattaat 780tcactacttc ctcacagctt ttttttggct ttacaaatcc actggaaagg tatatgggtg 840tatcactttg tgtatttcgg tgtgcatgtg tagaggggac aaaaatcctc tctcaaacta 900taaatattga gtatttgtgt attgaacatt tgctataact actaggtttc ttaaataatc 960ttaatatata aaatgatata gaaaaaggga aattatagtt cgtattattc atctaagtga 1020agagattaaa acccagggag taaataaatt gtctaaggac taaggttgta tactatttag 1080gtgatagata tggggcaacc gtatgggttt tatgattaac aaataaactt ctcaccactc 1140taccatatca acttttccat aaaagagagc tatagtattc tttgcttaaa taaatttgat 1200tagtgcatga cttcttgaaa acatataaag caaaagtcac atttgattct atcagaaaag 1260tgagtaagcc atggcccaaa caaaagatgc attaaaatat tctggaatga tggagctaaa 1320agtaagaaaa atgacttttt aaaaaagttt actgttagga attgtgaaat tatgctgaat 1380tttagttgca ttataatttt tgtcagtcat acggtctgac aacctgtctt atttctattt 1440ccccatatga ggaatgctag ttaagtatgg atattaacta ttactactta gatgcattga 1500agttgcataa tatggataat acttcactgg ttccctgaaa atgtttagtt agtaataagt 1560ctcttacact atttgttttg tccaataatt tatattttct gaagacttaa ctctagaata 1620cactcatgtc aaaatgaaag aatttcattg caaaatattg cttggtacat gacgcatacc 1680tgtatttgtt ttgtgtcaca acatgaaaaa tgatggttta ttagaagttt cattgggtag 1740gaaacacatt tgaatggtat ttactaagat actaaaatcc ttggacttca ctctaatttt 1800agtgccattt agaactcaag gtctcagtaa aagtagaaat aaagcctgtt aacaaaacac 1860aagctgaata ttaaaaatgt aactggattt tcaaagaaat gtttactggt attacctgta 1920gatgtatatt ctttattatg atcttttgtg taaagtctgg cagacaaatg caatatctaa 1980ttgttgagtc caatatcaca agcagtacaa aagtataaaa aagacttggc cttttctaat 2040gtgttaaaat actttatgct ggtaataaca ctaagagtag ggcactagaa attttaagtg 2100aagataatgt gttgcagtta ctgcactcaa tggcttacta ttataaacca aaactgggat 2160cactaagctc cagtcagtca aaatgatcaa aattattgaa gagaataagc aattctgttc 2220tttattagga cacagtagat acagactaca aagtggagtg tgcttaataa gaggtagcat 2280ttgttaagtg tcaattactc tattatccct tggagcttct caaaataacc atataaggtg 2340taagatgtta aaggttatgg ttacactcag tgcacaggta agctaatagg ctgagagaag 2400ctaaattact tactggggtc tcacagtaag aaagtgagct gaagtttcag cccagattta 2460actggattct gggctcttta ttcatgttac ttcatgaatc tgtttctcaa ttgtgcagaa 2520aaaagggggc tatttataag aaaagcaata aacaaacaag taatgatctc aaataagtaa 2580tgcaagaaat agtgagattt caaaatcagt ggcagcgatt tctcagttct gtcctaagtg 2640gccttgctca atcacctgct atcttttagt ggagctttga aattatgttt cagacaactt 2700cgattcagtt ctagaatgtt tgactcagca aattcacagg ctcatctttc taacttgatg 2760gtgaatatgg aaattcagct aaatggatgt taataaaatt caaacgtttt aaggacagat 2820gaaaatgaca gaattttaag gtaaaatata tgaaggaata taagataaag gatttttcta 2880ccttcagcaa aaacataccc actaattagt aaaattaata ggcaaaaaaa agttgcatgc 2940tcttatactg taatgattat cattttaaaa ctagcttttt gccttcgagc tatcggggta 3000aagacctaca ggaaaactac tgtcgaaatc ctcgagggga agaaggggga ccctggtgtt 3060tcacaagcaa tccagaggta cgctacgaag tctgtgacat tcctcagtgt tcagaagttg 3120aatgcatgac ctgcaatggg gagagttatc gaggtctcat ggatcataca gaatcaggca 3180agatttgtca gcgctgggat catcagacac cacaccggca caaattcttg cctgaaagat 3240atcccgacaa gggctttgat gataattatt gccgcaatcc cgatggccag ccgaggccat 3300ggtgctatac tcttgaccct cacacccgct gggagtactg tgcaattaaa acatgcgctg 3360acaatactat gaatgacact gatgttcctt tggaaacaac tgaatgcatc caaggtcaag 3420gagaaggcta caggggcact gtcaatacca tttggaatgg aattccatgt cagcgttggg 3480attctcagta tcctcacgag catgacatga ctcctgaaaa tttcaagtgc aaggacctac 3540gagaaaatta ctgccgaaat ccagatgggt ctgaatcacc ctggtgtttt accactgatc 3600caaacatccg agttggctac tgctcccaaa ttccaaactg tgatatgtca catggacaag 3660attgttatcg tgggaatggc aaaaattata tgggcaactt atcccaaaca agatctggac 3720taacatgttc aatgtgggac aagaacatgg aagacttaca tcgtcatatc ttctgggaac 3780cagatgcaag taagctgaat gagaattact gccgaaatcc agatgatgat gctcatggac 3840cctggtgcta cacgggaaat ccactcattc cttgggatta ttgccctatt tctcgttgtg 3900aaggtgatac cacacctaca atagtcaatt tagaccatcc cgtaatatct tgtgccaaaa 3960cgaaacaatt gcgagttgta aatgggattc caacacgaac aaacatagga tggatggtta 4020gtttgagata cagaaataaa catatctgcg gaggatcatt gataaaggag agttgggttc 4080ttactgcacg acagtgtttc ccttctcgag acttgaaaga ttatgaagct tggcttggaa 4140ttcatgatgt ccacggaaga ggagatgaga aatgcaaaca ggttctcaat gtttcccagc 4200tggtatatgg ccctgaagga tcagatctgg ttttaatgaa gcttgccagg cctgctgtcc 4260tggatgattt tgttagtacg attgatttac ctaattatgg atgcacaatt cctgaaaaga 4320ccagttgcag tgtttatggc tggggctaca ctggattgat caactatgat ggcctattac 4380gagtggcaca tctctatata atgggaaatg agaaatgcag ccagcatcat cgagggaagg 4440tgactctgaa tgagtctgaa atatgtgctg gggctgaaaa gattggatca ggaccatgtg 4500agggggatta tggtggccca cttgtttgtg agcaacataa aatgagaatg gttcttggtg 4560tcattgttcc tggtcgtgga tgtgccattc caaatcgtcc tggtattttt gtccgagtag 4620catattatgc aaaatggata cacaaaatta ttttaacata taaggtacca cagtcatag 4679133679DNAArtificial Sequencenucleotide sequence of HGF-X7 13atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180accaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggaacagta 420tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc 540tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660tgttaataaa atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg 720tatttgtgga tcctgggtag gaaacacatt tgaatggtat ttactaagat actaaaatcc 780ttggacttca ctctaatttt agtgccattt agaactcaag gtctcagtaa aagtagaaat 840aaagcctgtt aacaaaacac aaactgaata ttaaaaatgt aactggattt tcaaagaaat 900gtttactggt attacctgta gatgtatatt ctttattatg atcttttgtg taaagtctgg 960cagacaaatg caatatctaa ttgttgagtc caatatcaca agcagtacaa aagtataaaa 1020aagacttggc cttttctaat gtgttaaaat actttatgct ggtaataaca ctaagagtag 1080ggcactagaa attttaagtg aagataatgt gttgcagtta ctgcactcaa tggcttacta 1140ttataaacca aaactgggat cactaagctc cagtcagtca aaatgatcaa aattattgaa 1200gagaataagc aattctgttc tttattagga cacagtagat acagactaca aagtggagtg 1260tgcttaataa gaggtagcat ttgttaagtg tcaattactc tattatccct tggagcttct 1320caaaataacc atataaggtg taagatgtta aaggttatgg ttacactcag tgcacaggta 1380agctaatagg ctgagagaag ctaaattact tactggggtc tcacagtaag aaagtgagct 1440gaagtttcag cccagattta actggattct gggctcttta ttcatgttac ttcatgaatc 1500tgtttctcaa ttgtgcagaa aaaagggggc tatttataag aaaagcaata aacaaacaag 1560taatgatctc aaataagtaa tgcaagaaat agtgagattt caaaatcagt ggcagcgatt 1620tctcagttct gtcctaagtg gccttgctca atcacctgct atcttttagt ggagctttga 1680aattatgttt cagacaactt cgattcagtt ctagaatgtt tgactcagca aattcacagg 1740ctcatctttc taacttgatg gtgaatatgg aaattcagct aaatggatgt taataaaatt 1800caaacgtttt aaggacagat ggaaatgaca gaattttaag gtaaaatata tgaaggaata 1860taagataaag gatttttcta ccttcagcaa aaacataccc actaattagt aaaattaata 1920ggcgaaaaaa agttgcatgc tcttatactg taatgattat cattttaaaa ctagcttttt 1980gccttcgagc tatcggggta aagacctaca ggaaaactac tgtcgaaatc ctcgagggga 2040agaaggggga ccctggtgtt tcacaagcaa tccagaggta cgctacgaag tctgtgacat 2100tcctcagtgt tcagaagttg aatgcatgac ctgcaatggg gagagttatc gaggtctcat 2160ggatcataca gaatcaggca agatttgtca gcgctgggat catcagacac cacaccggca 2220caaattcttg cctgaaagat atcccgacaa gggctttgat gataattatt gccgcaatcc 2280cgatggccag ccgaggccat ggtgctatac tcttgaccct cacacccgct gggagtactg 2340tgcaattaaa acatgcgctg acaatactat gaatgacact gatgttcctt tggaaacaac 2400tgaatgcatc caaggtcaag gagaaggcta caggggcact gtcaatacca tttggaatgg 2460aattccatgt cagcgttggg attctcagta tcctcacgag catgacatga ctcctgaaaa 2520tttcaagtgc aaggacctac gagaaaatta ctgccgaaat ccagatgggt ctgaatcacc 2580ctggtgtttt accactgatc caaacatccg agttggctac tgctcccaaa ttccaaactg 2640tgatatgtca catggacaag attgttatcg tgggaatggc aaaaattata tgggcaactt 2700atcccaaaca agatctggac taacatgttc aatgtgggac aagaacatgg aagacttaca 2760tcgtcatatc ttctgggaac cagatgcaag taagctgaat gagaattact gccgaaatcc 2820agatgatgat gctcatggac cctggtgcta cacgggaaat ccactcattc cttgggatta 2880ttgccctatt tctcgttgtg aaggtgatac cacacctaca atagtcaatt tagaccatcc 2940cgtaatatct tgtgccaaaa cgaaacaatt gcgagttgta aatgggattc caacacgaac 3000aaacatagga tggatggtta gtttgagata cagaaataaa catatctgcg gaggatcatt 3060gataaaggag agttgggttc ttactgcacg acagtgtttc ccttctcgag acttgaaaga 3120ttatgaagct tggcttggaa ttcatgatgt ccacggaaga ggagatgaga aatgcaaaca 3180ggttctcaat gtttcccagc tggtatatgg ccctgaagga tcagatctgg ttttaatgaa 3240gcttgccagg cctgctgtcc tggatgattt tgttagtacg attgatttac ctaattatgg 3300atgcacaatt cctgaaaaga ccagttgcag tgtttatggc tggggctaca ctggattgat 3360caactatgat ggcctattac gagtggcaca tctctatata atgggaaatg agaaatgcag 3420ccagcatcat cgagggaagg tgactctgaa tgagtctgaa atatgtgctg gggctgaaaa 3480gattggatca ggaccatgtg agggggatta tggtggccca cttgtttgtg agcaacataa 3540aatgagaatg gttcttggtg tcattgttcc tggtcgtgga tgtgccattc caaatcgtcc 3600tggtattttt gtccgagtag catattatgc aaaatggata cacaaaatta ttttaacata 3660taaggtacca cagtcatag 3679142729DNAArtificial Sequencenucleotide sequence of HGF-X8 14atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180accaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggaacagta 420tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc 540tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660tgttaataaa atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg 720tatttgtgga tccttatgtt tcagacaact tcgattcagt tctagaatgt ttgactcagc 780aaattcacag gctcatcttt ctaacttgat ggtgaatatg gaaattcagc taaatggatg 840ttaataaaat tcaaacgttt taaggacaga tgaaaatgac agaattttaa ggtaaaatat 900atgaaggaat ataagataaa ggatttttct accttcagca aaaacatacc cactaattag 960taaaattaat aggcaaaaaa aagttgcatg ctcttatact gtaatgatta tcattttaaa 1020actagctttt tgccttcgag ctatcggggt aaagacctac aggaaaacta ctgtcgaaat 1080cctcgagggg aagaaggggg accctggtgt ttcacaagca atccagaggt acgctacgaa 1140gtctgtgaca ttcctcagtg ttcagaagtt gaatgcatga cctgcaatgg ggagagttat 1200cgaggtctca tggatcatac agaatcaggc aagatttgtc agcgctggga tcatcagaca 1260ccacaccggc acaaattctt gcctgaaaga tatcccgaca agggctttga tgataattat 1320tgccgcaatc ccgatggcca gccgaggcca tggtgctata ctcttgaccc tcacacccgc 1380tgggagtact gtgcaattaa aacatgcgct gacaatacta tgaatgacac tgatgttcct 1440ttggaaacaa ctgaatgcat ccaaggtcaa ggagaaggct acaggggcac tgtcaatacc 1500atttggaatg gaattccatg tcagcgttgg gattctcagt atcctcacga gcatgacatg 1560actcctgaaa atttcaagtg caaggaccta cgagaaaatt actgccgaaa tccagatggt 1620ctgaatcacc ctggtgtttt accactgatc caaacatccg agttggctac tgctcccaaa 1680ttccaaactg tgatatgtca catggacaag attgttatcg tgggaatggc aaaaattata 1740tgggcaactt atcccaaaca agatctggac taacatgttc aatgtgggac aagaacatgg 1800aagacttaca tcgtcatatc ttctgggaac cagatgcaag taagctgaat gagaattact 1860gccgaaatcc agatgatgat gctcatggac cctggtgcta cacgggaaat ccactcattc 1920cttgggatta ttgccctatt tctcgttgtg aaggtgatac cacacctaca atagtcaatt 1980tagaccatcc cgtaatatct tgtgccaaaa cgaaacaatt gcgagttgta aatgggattc 2040caacacgaac aaacatagga tggatggtta gtttgagata cagaaataaa catatctgcg 2100gaggatcatt gataaaggag agttgggttc ttactgcacg acagtgtttc ccttctcgag 2160acttgaaaga ttatgaagct tggcttggaa ttcatgatgt ccacggaaga ggagatgaga 2220aatgcaaaca ggttctcaat gtttcccagc tggtatatgg ccctgaagga tcagatctgg 2280ttttaatgaa gcttgccagg cctgctgtcc tggatgattt tgttagtacg attgatttac 2340ctaattatgg atgcacaatt cctgaaaaga ccagttgcag tgtttatggc tggggctaca 2400ctggattgat caactatgat ggcctattac gagtggcaca tctctatata atgggaaatg 2460agaaatgcag ccagcatcat cgagggaagg tgactctgaa tgagtctgaa atatgtgctg 2520gggctgaaaa gattggatca ggaccatgtg agggggatta tggtggccca cttgtttgtg 2580agcaacataa aatgagaatg gttcttggtg tcattgttcc tggtcgtgga tgtgccattc 2640caaatcgtcc tggtattttt gtccgagtag catattatgc aaaatggata cacaaaatta 2700ttttaacata taaggtacca cagtcatag 27291526DNAArtificial Sequenceforward primer 15caaatgtcag ccctggagtt ccatga 261626DNAArtificial Sequencereverse primer 16ctggattgct tgtgaaacac cagggt 26

Claims

1. A pharmaceutical composition for the prevention or treatment of diabetic neuropathy, the composition comprising, as active ingredients, different types of isoforms of hepatocyte growth factor (HGF) or at least one polynucleotide encoding the isoforms.